https://www.limswiki.org/api.php?action=feedcontributions&user=Rthiggins&feedformat=atomLIMSWiki - User contributions [en]2024-03-28T19:50:16ZUser contributionsMediaWiki 1.36.1https://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34060User:Rthiggins/StateCannabisTestingRegulations2018-10-21T16:38:15Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
<br />
# Legal status of cannabis<br />
# Regulatory Authority<br />
# Regulatory scheme and titles of applicable statutes/codes<br />
# Testing facility licensing/registration requirements<br />
# Testing facility physical plant requirements (include security requirements here)<br />
# Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795<br />
# Personnel Requirements, Qualifications, Registration/Licensure<br />
# Inventory Tracking and handling of samples received by lab for testing<br />
# Sampling for testing requirements/methods<br />
# Products that require testing<br />
# Specific required tests for each product type<br />
# Required method for conducting required tests<br />
# Method validation, if no method is mandated and the lab develops its own testing method<br />
# Reporting results of testing (who, what, where, when, how)<br />
# QA/QC requirements (of the laboratory and lab practices<br />
# Record keeping requirements<br />
<br />
==States (US)==<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alabama | Alabama]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Arizona | Arizona]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Arkansas | Arkansas]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/California | California]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Colorado | Colorado]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Connecticut | Connecticut]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Delaware | Delaware]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/DistrictofColumbia | District of Columbia]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Florida | Florida]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Georgia | Georgia]]<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Hawaii | Hawaii]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Idaho | Idaho]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Illinois | Illinois]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Indiana | Indiana]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Iowa | Iowa]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Kansas | Kansas]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Kentucky | Kentucky]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Louisiana | Louisiana]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Maine | Maine]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Maryland | Maryland]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Massachusetts | Massachusetts]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Michigan | Michigan]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Minnesota | Minnesota]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Mississippi | Mississippi]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Missouri | Missouri]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Nebraska | Nebraska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Nevada | Nevada]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Hampshire | New Hampshire]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Jersey | New Jersey]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New York | New York]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/North Carolina | North Carolina]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/North Dakota | North Dakota]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Ohio | Ohio]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Oklahoma | Oklahoma]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Oregon | Oregon]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Pennsylvania | Pennsylvania]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Rhode Island | Rhode Island]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/South Carolina | South Carolina]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/South Dakota | South Dakota]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Tennessee | Tennessee]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Texas | Texas]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Utah | Utah]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Vermont | Vermont]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Virginia | Virginia]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Washington | Washington]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/West Virginia | West Virginia]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Wisconsin | Wisconsin]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Wyoming | Wyoming]]<br />
<br />
==Canada==<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Canada | Canada]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Alabama&diff=34054User:Rthiggins/StateCannabisTestingRegulations/Alabama2018-10-14T21:51:49Z<p>Rthiggins: Created page with "=Legal status= * Cannabis in any form remains illegal to grow, possess, distribute, or use in the state of Alabama, except by persons or agencies authorized to work with Sched..."</p>
<hr />
<div>=Legal status=<br />
* Cannabis in any form remains illegal to grow, possess, distribute, or use in the state of Alabama, except by persons or agencies authorized to work with Schedule I CDS. Criminal penalties are harsh.<br />
<br />
* Cannabidiol oil was decriminalized in 2016. However, it remains illegal to have or use within the state. The law creates an "affirmative defense" for patients with very specific and limited diseases (seizures) who are found in possession of it. This means they arrest and charge first, then you have to sort it out in court.<br />
<br />
* CBD oil in Alabama may contain up to 3% THC, but there don't appear to be any requirements or provisions for verifying that number.</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34051User:Rthiggins/StateCannabisTestingRegulations2018-10-14T12:31:15Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
<br />
# Legal status of cannabis<br />
# Regulatory Authority<br />
# Regulatory scheme and titles of applicable statutes/codes<br />
# Testing facility licensing/registration requirements<br />
# Testing facility physical plant requirements (include security requirements here)<br />
# Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795<br />
# Personnel Requirements, Qualifications, Registration/Licensure<br />
# Inventory Tracking and handling of samples received by lab for testing<br />
# Sampling for testing requirements/methods<br />
# Products that require testing<br />
# Specific required tests for each product type<br />
# Required method for conducting required tests<br />
# Method validation, if no method is mandated and the lab develops its own testing method<br />
# Reporting results of testing (who, what, where, when, how)<br />
# QA/QC requirements (of the laboratory and lab practices<br />
# Record keeping requirements<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alabama | Alabama]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Arizona | Arizona]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Arkansas | Arkansas]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/California | California]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Colorado | Colorado]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Connecticut | Connecticut]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Delaware | Delaware]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/DistrictofColumbia | District of Columbia]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Florida | Florida]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Georgia | Georgia]]<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Hawaii | Hawaii]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Idaho | Idaho]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Illinois | Illinois]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Indiana | Indiana]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Iowa | Iowa]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Kansas | Kansas]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Kentucky | Kentucky]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Louisiana | Louisiana]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Maine | Maine]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Maryland | Maryland]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Massachusetts | Massachusetts]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Michigan | Michigan]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Minnesota | Minnesota]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Mississippi | Mississippi]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Missouri | Missouri]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Nebraska | Nebraska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Nevada | Nevada]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Hampshire | New Hampshire]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Jersey | New Jersey]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New York | New York]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/North Carolina | North Carolina]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/North Dakota | North Dakota]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Ohio | Ohio]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Oklahoma | Oklahoma]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Oregon | Oregon]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Pennsylvania | Pennsylvania]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Rhode Island | Rhode Island]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/South Carolina | South Carolina]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/South Dakota | South Dakota]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Tennessee | Tennessee]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Texas | Texas]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Utah | Utah]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Vermont | Vermont]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Virginia | Virginia]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Washington | Washington]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/West Virginia | West Virginia]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Wisconsin | Wisconsin]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Wyoming | Wyoming]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Colorado&diff=34050User:Rthiggins/StateCannabisTestingRegulations/Colorado2018-10-14T04:06:50Z<p>Rthiggins: </p>
<hr />
<div>Colorado Marijuana Testing Requirements<br />
<br />
=Information resources=<br />
[http://www.moderncanna.com/resources/colorado/ Colorado Cannabis Testing Regulations - Modern Canna Science]<br />
<br />
=Legal resources=<br />
==Statutory law==<br />
C.R.S. 44 (Revenue - Regulation of Activities - Marijuana Regulation) 11 - Medical<br />
<br />
C.R.S. 44 (Revenue - Regulation of Activities - Marijuana Regulation) 12 - Retail<br />
<br />
<br />
==Code of Colorado Regulations (C.C.R.)==<br />
===1 CCR 212-2 Retail Marijuana Rules===<br />
{| class="wikitable" border="1"<br />
|-<br />
! Rule series number<br />
! Series title<br />
! Subject matter<br />
|-<br />
| R700<br />
| Retail Marijuana Testing Facilities<br />
| Licensing; certification facilities/staff; SOP requirements; analytical process requirements; proficiency testing; QA/QC; recordkeeping/retention; reporting and inventory tracking; sampling and testing program<br />
|-<br />
| R1500<br />
| Retail Marijuana Testing Program<br />
| Contaminant testing; mandatory testing; potency testing; sampling procedures; testing program costs; failed/contaminated batch handling<br />
|}<br />
* R700 series - Retail Marijuana Testing Facilities (covers licensing and certification of facilities and staff,</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Colorado&diff=34049User:Rthiggins/StateCannabisTestingRegulations/Colorado2018-10-13T19:02:47Z<p>Rthiggins: </p>
<hr />
<div>=Colorado Marijuana Testing Requirements=<br />
<br />
==Information resources==<br />
[http://www.moderncanna.com/resources/colorado/ Colorado Cannabis Testing Regulations - Modern Canna Science]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Colorado&diff=34048User:Rthiggins/StateCannabisTestingRegulations/Colorado2018-10-13T18:59:58Z<p>Rthiggins: Created page with "=Colorado Marijuana Testing Requirements="</p>
<hr />
<div>=Colorado Marijuana Testing Requirements=</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34031User:Rthiggins/StateCannabisTestingRegulations2018-09-30T23:36:57Z<p>Rthiggins: Added Colorado page link</p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
<br />
===Legal status of cannabis===<br />
<br />
===Regulatory Authority===<br />
<br />
===Regulatory scheme and titles of applicable statutes/codes===<br />
<br />
===Testing facility licensing/registration requirements===<br />
<br />
===Testing facility physical plant requirements (include security requirements here)===<br />
<br />
===Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795===<br />
<br />
===Personnel Requirements, Qualifications, Registration/Licensure===<br />
<br />
===Inventory Tracking and handling of samples received by lab for testing===<br />
<br />
===Sampling for testing requirements/methods===<br />
<br />
===Products that require testing===<br />
<br />
===Specific required tests for each product type===<br />
<br />
===Required method for conducting required tests===<br />
<br />
===Method validation, if no method is mandated and the lab develops its own testing method===<br />
<br />
===Reporting results of testing (who, what, where, when, how)===<br />
<br />
===QA/QC requirements (of the laboratory and lab practices===<br />
<br />
===Record keeping requirements===<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Massachusetts | Massachusetts]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Maine | Maine]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Vermont | Vermont]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Colorado | Colorado]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Vermont&diff=34030User:Rthiggins/StateCannabisTestingRegulations/Vermont2018-09-30T23:35:45Z<p>Rthiggins: </p>
<hr />
<div>==References saved or available==<br />
<br />
<br />
[https://www.burlingtonfreepress.com/story/news/politics/government/2018/06/11/vermont-marijuana-fails-adapt-medical-program-legalization-weed/644281002/ Vermont Medical vs Retail Conflicting Law]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Vermont&diff=34029User:Rthiggins/StateCannabisTestingRegulations/Vermont2018-09-30T22:32:10Z<p>Rthiggins: Created page with "==References saved or available=="</p>
<hr />
<div>==References saved or available==</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34028User:Rthiggins/StateCannabisTestingRegulations2018-09-30T22:29:09Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
<br />
===Legal status of cannabis===<br />
<br />
===Regulatory Authority===<br />
<br />
===Regulatory scheme and titles of applicable statutes/codes===<br />
<br />
===Testing facility licensing/registration requirements===<br />
<br />
===Testing facility physical plant requirements (include security requirements here)===<br />
<br />
===Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795===<br />
<br />
===Personnel Requirements, Qualifications, Registration/Licensure===<br />
<br />
===Inventory Tracking and handling of samples received by lab for testing===<br />
<br />
===Sampling for testing requirements/methods===<br />
<br />
===Products that require testing===<br />
<br />
===Specific required tests for each product type===<br />
<br />
===Required method for conducting required tests===<br />
<br />
===Method validation, if no method is mandated and the lab develops its own testing method===<br />
<br />
===Reporting results of testing (who, what, where, when, how)===<br />
<br />
===QA/QC requirements (of the laboratory and lab practices===<br />
<br />
===Record keeping requirements===<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Massachusetts | Massachusetts]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Maine | Maine]]<br />
<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Vermont | Vermont]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Maine&diff=34027User:Rthiggins/StateCannabisTestingRegulations/Maine2018-09-30T22:23:30Z<p>Rthiggins: Created page with "==Reference documents saved or available== * Maine 10-144c122 Medical Marijuana Rules 2-1-2018 * [http://legislature.maine.gov/statutes/7/title7sec2445.html Maine Statutes T..."</p>
<hr />
<div>==Reference documents saved or available==<br />
<br />
* Maine 10-144c122 Medical Marijuana Rules 2-1-2018<br />
<br />
* [http://legislature.maine.gov/statutes/7/title7sec2445.html Maine Statutes Title 7 Section 2445 Independent Testing]<br />
<br />
* [http://legislature.maine.gov/statutes/7/title7sec2448.html Maine Statutes Title 7 Section 2448 Classes of Licenses]<br />
<br />
===Status===<br />
New statutes effective February 1, 2018, require testing of marijuana and marijuana products to be sold on the retail (non-medical) market. It does not appear that rules have yet been promulgated to address the details of implementing such a program. These rules are the responsibility of the Commissioner of Agriculture, Conservation, and Forestry.</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34026User:Rthiggins/StateCannabisTestingRegulations2018-09-30T21:21:56Z<p>Rthiggins: Added Maine page</p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
<br />
===Legal status of cannabis===<br />
<br />
===Regulatory Authority===<br />
<br />
===Regulatory scheme and titles of applicable statutes/codes===<br />
<br />
===Testing facility licensing/registration requirements===<br />
<br />
===Testing facility physical plant requirements (include security requirements here)===<br />
<br />
===Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795===<br />
<br />
===Personnel Requirements, Qualifications, Registration/Licensure===<br />
<br />
===Inventory Tracking and handling of samples received by lab for testing===<br />
<br />
===Sampling for testing requirements/methods===<br />
<br />
===Products that require testing===<br />
<br />
===Specific required tests for each product type===<br />
<br />
===Required method for conducting required tests===<br />
<br />
===Method validation, if no method is mandated and the lab develops its own testing method===<br />
<br />
===Reporting results of testing (who, what, where, when, how)===<br />
<br />
===QA/QC requirements (of the laboratory and lab practices===<br />
<br />
===Record keeping requirements===<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Massachusetts | Massachusetts]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Maine | Maine]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Massachusetts&diff=34025User:Rthiggins/StateCannabisTestingRegulations/Massachusetts2018-09-30T21:20:40Z<p>Rthiggins: </p>
<hr />
<div>==Reference documents saved or available==<br />
* Massachusetts Laboratory Quality Assurance Program Plan (PDF)<br />
* MDPH-MMJ-MIPS Testing Protocol for Marijuana and Marijuana Products (PDF)<br />
* Guidance Doc - Third Party ISO Accreditation (.docx)<br />
* Exhibit 1 - Production Overview (PDF)<br />
* Exhibit 2 - Testing Requirements (PDF)<br />
* Exhibit 3 - Representative Sampling (PDF)<br />
* Exhibit 4 - Heavy Metal Limits (PDF)<br />
* Exhibit 5 - Pesticide List (PDF)<br />
* Exhibit 6 - Microbe Limits (PDF)<br />
* Exhibit 7 - Residual Solvent Limits (PDF)<br />
* Exhibit 8 - Response to Lab Results (PDF)<br />
* Hydrocarbon Revised Limits 11-23-16 (PDF)<br />
<br />
===Legal status of cannabis===<br />
Legalized for recreational (2016) and medical use (2013). <br />
<br />
<br />
===Regulatory Authority===<br />
Medical: Department of Health<br />
Recreational: Cannabis Control Commission<br />
<br />
===Regulatory scheme and titles of applicable statutes/codes===<br />
105 CMR 725.031 Registration of Independent Testing Laboratories (medical)<br />
935 CMR 500.160 Testing of Marijuana and Marijuana Products (recreational, but just refers to the same protocol used by the medical testing)<br />
'Protocol for Sampling and Analysis of Finished Medical <br />
Marijuana Products and Marijuana-Infused Products'<br />
'Protocol for Sampling and Analysis of Environmental Media for Massachusetts Registered Medical Marijuana Dispensaries'<br />
<br />
<br />
===Testing facility licensing/registration requirements===<br />
Medical: Licensing required; medical testing license does not permit testing of recreational product unless a separate license is obtained<br />
Recreational: Licensure required; to date, no licenses have been granted (1 in works); <br />
<br />
===Testing facility physical plant requirements (include security requirements here)===<br />
<br />
===Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795===<br />
<br />
===Personnel Requirements, Qualifications, Registration/Licensure===<br />
<br />
===Inventory Tracking and handling of samples received by lab for testing===<br />
<br />
===Sampling for testing requirements/methods===<br />
<br />
===Products that require testing===<br />
<br />
===Specific required tests for each product type===<br />
<br />
===Required method for conducting required tests===<br />
<br />
===Method validation, if no method is mandated and the lab develops its own testing method===<br />
<br />
===Reporting results of testing (who, what, where, when, how)===<br />
<br />
===QA/QC requirements (of the laboratory and lab practices===<br />
<br />
===Record keeping requirements===</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Massachusetts&diff=34024User:Rthiggins/StateCannabisTestingRegulations/Massachusetts2018-09-30T00:39:34Z<p>Rthiggins: </p>
<hr />
<div>==General information template for each state==<br />
<br />
===Legal status of cannabis===<br />
Legalized for recreational (2016) and medical use (2013). <br />
<br />
<br />
===Regulatory Authority===<br />
Medical: Department of Health<br />
Recreational: Cannabis Control Commission<br />
<br />
===Regulatory scheme and titles of applicable statutes/codes===<br />
105 CMR 725.031 Registration of Independent Testing Laboratories (medical)<br />
935 CMR 500.160 Testing of Marijuana and Marijuana Products (recreational, but just refers to the same protocol used by the medical testing)<br />
'Protocol for Sampling and Analysis of Finished Medical <br />
Marijuana Products and Marijuana-Infused Products'<br />
'Protocol for Sampling and Analysis of Environmental Media for Massachusetts Registered Medical Marijuana Dispensaries'<br />
<br />
<br />
===Testing facility licensing/registration requirements===<br />
Medical: Licensing required; medical testing license does not permit testing of recreational product unless a separate license is obtained<br />
Recreational: Licensure required; to date, no licenses have been granted (1 in works); <br />
<br />
===Testing facility physical plant requirements (include security requirements here)===<br />
<br />
===Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795===<br />
<br />
===Personnel Requirements, Qualifications, Registration/Licensure===<br />
<br />
===Inventory Tracking and handling of samples received by lab for testing===<br />
<br />
===Sampling for testing requirements/methods===<br />
<br />
===Products that require testing===<br />
<br />
===Specific required tests for each product type===<br />
<br />
===Required method for conducting required tests===<br />
<br />
===Method validation, if no method is mandated and the lab develops its own testing method===<br />
<br />
===Reporting results of testing (who, what, where, when, how)===<br />
<br />
===QA/QC requirements (of the laboratory and lab practices===<br />
<br />
===Record keeping requirements===</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Massachusetts&diff=34020User:Rthiggins/StateCannabisTestingRegulations/Massachusetts2018-09-25T23:58:26Z<p>Rthiggins: Created page with "==General information template for each state== ===Legal status of cannabis=== Legalized for recreational (2016) and medical use (2013). ===Regulatory Authority=== Medical..."</p>
<hr />
<div>==General information template for each state==<br />
<br />
===Legal status of cannabis===<br />
Legalized for recreational (2016) and medical use (2013). <br />
<br />
<br />
===Regulatory Authority===<br />
Medical: Department of Health<br />
Recreational: Cannabis Control Commission<br />
<br />
===Regulatory scheme and titles of applicable statutes/codes===<br />
<br />
<br />
<br />
===Testing facility licensing/registration requirements===<br />
Medical: Licensing required; medical testing license does not permit testing of recreational product unless a separate license is obtained<br />
Recreational: Licensure required; to date, no licenses have been granted (1 in works); <br />
<br />
===Testing facility physical plant requirements (include security requirements here)===<br />
<br />
===Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795===<br />
<br />
===Personnel Requirements, Qualifications, Registration/Licensure===<br />
<br />
===Inventory Tracking and handling of samples received by lab for testing===<br />
<br />
===Sampling for testing requirements/methods===<br />
<br />
===Products that require testing===<br />
<br />
===Specific required tests for each product type===<br />
<br />
===Required method for conducting required tests===<br />
<br />
===Method validation, if no method is mandated and the lab develops its own testing method===<br />
<br />
===Reporting results of testing (who, what, where, when, how)===<br />
<br />
===QA/QC requirements (of the laboratory and lab practices===<br />
<br />
===Record keeping requirements===</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34019User:Rthiggins/StateCannabisTestingRegulations2018-09-25T23:16:11Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
<br />
===Legal status of cannabis===<br />
<br />
===Regulatory Authority===<br />
<br />
===Regulatory scheme and titles of applicable statutes/codes===<br />
<br />
===Testing facility licensing/registration requirements===<br />
<br />
===Testing facility physical plant requirements (include security requirements here)===<br />
<br />
===Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795===<br />
<br />
===Personnel Requirements, Qualifications, Registration/Licensure===<br />
<br />
===Inventory Tracking and handling of samples received by lab for testing===<br />
<br />
===Sampling for testing requirements/methods===<br />
<br />
===Products that require testing===<br />
<br />
===Specific required tests for each product type===<br />
<br />
===Required method for conducting required tests===<br />
<br />
===Method validation, if no method is mandated and the lab develops its own testing method===<br />
<br />
===Reporting results of testing (who, what, where, when, how)===<br />
<br />
===QA/QC requirements (of the laboratory and lab practices===<br />
<br />
===Record keeping requirements===<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Massachusetts | Massachusetts]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34014User:Rthiggins/StateCannabisTestingRegulations2018-09-23T19:47:19Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
<br />
===Legal status of cannabis===<br />
<br />
===Regulatory Authority===<br />
<br />
===Regulatory scheme and titles of applicable statutes/codes===<br />
<br />
===Testing facility licensing/registration requirements===<br />
<br />
===Testing facility physical plant requirements (include security requirements here)===<br />
<br />
===Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795===<br />
<br />
===Personnel Requirements, Qualifications, Registration/Licensure===<br />
<br />
===Inventory Tracking and handling of samples received by lab for testing===<br />
<br />
===Sampling for testing requirements/methods===<br />
<br />
===Products that require testing===<br />
<br />
===Specific required tests for each product type===<br />
<br />
===Required method for conducting required tests===<br />
<br />
===Method validation, if no method is mandated and the lab develops its own testing method===<br />
<br />
===Reporting results of testing (who, what, where, when, how)===<br />
<br />
===QA/QC requirements (of the laboratory and lab practices===<br />
<br />
===Record keeping requirements===<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34013User:Rthiggins/StateCannabisTestingRegulations2018-09-22T21:08:40Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
<br />
==Legal status of cannabis==<br />
<br />
==Regulatory Authority==<br />
<br />
==Regulatory scheme and titles of applicable statutes/codes==<br />
<br />
==Testing facility licensing/registration requirements==<br />
<br />
==Testing facility physical plant requirements (include security requirements here)==<br />
<br />
==Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795==<br />
<br />
==Personnel Requirements, Qualifications, Registration/Licensure==<br />
<br />
==Inventory Tracking and handling of samples received by lab for testing==<br />
<br />
==Sampling for testing requirements/methods==<br />
<br />
==Products that require testing==<br />
<br />
==Specific required tests for each product type==<br />
<br />
==Required method for conducting required tests==<br />
<br />
==Method validation, if no method is mandated and the lab develops its own testing method==<br />
<br />
==Reporting results of testing (who, what, where, when, how)==<br />
<br />
==QA/QC requirements (of the laboratory and lab practices==<br />
<br />
==Record keeping requirements==<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/New_Mexico&diff=34012User:Rthiggins/StateCannabisTestingRegulations/New Mexico2018-09-22T20:54:57Z<p>Rthiggins: Created page with "New Mexico permits medical use of cannabis by qualified patients (QPs) and their Primary Caregivers (PG) who are registered with the state medical cannabis program."</p>
<hr />
<div>New Mexico permits medical use of cannabis by qualified patients (QPs) and their Primary Caregivers (PG) who are registered with the state medical cannabis program.</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34011User:Rthiggins/StateCannabisTestingRegulations2018-09-22T20:49:26Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
# Legal status of cannabis <br />
# Regulatory Authority<br />
# Regulatory scheme and titles of applicable statutes/codes<br />
# Testing facility licensing/registration requirements<br />
# Testing facility physical plant requirements (include security requirements here)<br />
# Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795<br />
# Personnel Requirements, Qualifications, Registration/Licensure<br />
# Inventory Tracking and handling of samples received by lab for testing<br />
# Sampling for testing requirements/methods<br />
# Products that require testing<br />
# Specific required tests for each product type<br />
# Required method for conducting required tests<br />
# Method validation, if no method is mandated and the lab develops its own testing method<br />
# Reporting results of testing (who, what, where, when, how)<br />
# QA/QC requirements<br />
# Record keeping requirements<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34010User:Rthiggins/StateCannabisTestingRegulations2018-09-22T20:48:47Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
# Legal status of cannabis <br />
# Regulatory Authority<br />
# Regulatory scheme and titles of applicable statutes/codes<br />
# Testing facility licensing/registration requirements<br />
# Testing facility physical plant requirements (include security requirements here)<br />
# Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795<br />
# Personnel Requirements, Qualifications, Registration/Licensure<br />
# Inventory Tracking and handling of samples received by lab for testing<br />
# Sampling for testing requirements/methods<br />
# Products that require testing<br />
# Specific required tests for each product type<br />
# Required method for conducting required tests<br />
# Method validation, if no method is mandated and the lab develops its own testing method<br />
# Reporting results of testing (who, what, where, when, how)<br />
# QA/QC requirements<br />
# Record keeping requirements<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]<br />
[[User:Rthiggins/StateCannabisTestingRegulations/New Mexico | New Mexico]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Alaska&diff=34007User:Rthiggins/StateCannabisTestingRegulations/Alaska2018-09-18T19:47:33Z<p>Rthiggins: </p>
<hr />
<div><br />
==Regulatory scheme==<br />
Medical use of marijuana was legalized in Alaska after the 1998 election. The law allows certified physicians to recommend treatment with medical marijuana to their patients with qualifying debilitating diseases. Patients must register with the state, and thereafter may legally possess, use, and cultivate limited quantities of marijuana.<ref name='LeafbuyerFrequently18'>{{cite web short |url=https://www.leafbuyer.com/alaska |title=Frequently Asked Questions About Marijuana in Alaska |date=25 May 2018 |accessdate=14 September 2018}}</ref><br />
<br />
The law authorizing marijuana for medical use does not provide guidance or regulation related to the legal opening and operation of marijuana dispensaries within the state. With the approval of adult-use of marijuana, effective 2016, new regulatory structures were codified that cover all aspects of the marijuana industry in Alaska. Medical and retail marijuana now share a common set of regulations, including those for inventory tracking and laboratory testing.<ref name='LeafbuyerFrequently18'></ref><br />
<br />
==Licensing requirements==<br />
Alaska defines four types of marijuana establishments: retail marijuana store, marijuana cultivation facilities, marijuana product manufacturing facilities, and marijuana testing facilities. All establishments must be licensed by the Marijuana Control Board, and each of the four types has its own license.<br />
<br />
===Marijuana testing facilities===<br />
A person or organization may not offer or provide marijuana testing services or results unless they have applied for and obtained a Marijuana Testing Facility license. There is an initial application that is common to all establishments, followed by a supplemental application for the specific type of facility. Testing facility icensing requirements do not apply to a licensed marijuana establishment that conducts in-house testing using its own equipment to test material produced within the same facility.<br />
<br />
====Conflict of interest====<br />
The code specifically states that a holder of a marijuana testing facility license may not hold another type of marijuana license in Alaska. Further, the licensee, or any employee or agent of the licensed testing facility are prohibited from having an ownership interest or direct or indirect financial interest in another licensed marijuana establishment within the state. Finally, the licensee may not have a financial interest in common with a person who holds a license in Alaska for a marijuana establishment other than a testing facility.<br />
<br />
<br />
====Privileges and prohibitions====<br />
Licensed marijuana testing facilities may have any amount of marijuana/products on premises at any given time as long as facility inventory tracking system used and indicates all marijuana on site is for testing purposes. However, distribution, sale, or transfer of marijuana directly to a consumer is prohibited, as is consumption of marijuana by anyone while on the premises of the testing facility.<br />
<br />
===SOP requirements===<br />
Testing facilities must have a written manual of standard operating procedures (SOPs) on site and available to all employees at all times. It must provide detailed instructions on how to perform each testing method the facility uses, as well as the minimum standards for each test. The SOP manual must cover:<br />
* Sample preparation for each matrix that will be tested<br />
<br />
* Reagent, solution, and reference standard preparation<br />
<br />
* Instrument setup, if applicable<br />
<br />
* Data acquisition<br />
<br />
* Calculation of results<br />
<br />
* Identification criteria<br />
<br />
* Quality control frequency<br />
<br />
* Quality control acceptance criteria<br />
<br />
* Corrective action protocols<br />
<br />
<br />
Personnel qualifications<br />
====Scientific director==== <br />
(3 AAC 306.630. Scientific director)<br />
LMTFs must employ a scientific director who is responsible for managing and directing laboratory operations within the testing facility; the scientific director will also be responsible for supervising all staff at the facility, and ensuring the work done in the laboratory meets required quality standards. The person filling this role must meet minimum education/experience qualifications by holding:<br />
<br />
* A doctorate degree in chemical or biological sciences with at least two years post-degree lab experience, or<br />
<br />
* A master's degree in chemical or biological sciences with at least four years post-degree lab experience, or<br />
<br />
* A bachelor's degree in chemical or biological sciences with at least six years post-degree lab experience<br />
<br />
====Marijuana handler permit====<br />
Per the general operating requirements for all marijuana establishments (3 AAC 306.700. "Article 7"), all licensees, employees, agents of a licensed marijuana establishment who sell, cultivate, manufacture, test, or transport marijuana in any form, or who check identification of consumers or visitors, must apply for and obtain a marijuana handler permit prior to beginning employment at the establishment. <br />
<br />
Applicants must first complete an education course approved by the Marijuana Control Board that addresses topics such as the statutory law and codes governing the marijuana industry in Alaska; the effects of consumption of marijuana; identifying a person who is impaired by marijuana consumption; how to determine valid identification; how to intervene to prevent unlawful marijuana consumption; and the penalties for unlawful acts by a licensee, an employee, or agent of a marijuana establishment. After completing the course, applicants must demonstrate they understand the material by passing a written test. A permit is then issued as long as the person meets certain criteria for a criminal background check. 3 AAC 306.700.(f) (Marijuana handler permit - DQs)<br />
<br />
Handling permits must be in the holder's immediate possession or a valid copy on file in the testing facility at all times when on the premises. Permits may be renewed every three years upon passing another written exam. <br />
<br />
6. Testing Required<br />
<br />
===Physical Plant Reqs===<br />
3 AAC 306.715. Security alarm systems and lock standards<br />
3 AAC 306.720. Video surveillance<br />
<br />
Upcoming Changes to Alaska Administrative Code<br />
A number of changes have been proposed to 3 AAC 306 et seq, and have been held out for public comment/objections. Hearing will be in mid-December 2018. These changes pertain only to the creation of an endorsement to the retail cannabis store license that permits consumption of cannabis and associated products on-premises. The endorsement only affects retail stores, with no lab implications.<br />
<br />
== References ==<br />
{{Reflist}}</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Alaska&diff=34006User:Rthiggins/StateCannabisTestingRegulations/Alaska2018-09-17T00:06:12Z<p>Rthiggins: </p>
<hr />
<div><br />
==Regulatory scheme==<br />
Medical use of marijuana was legalized in Alaska after the 1998 election. The law allows certified physicians to recommend treatment with medical marijuana to their patients with qualifying debilitating diseases. Patients must register with the state, and thereafter may legally possess, use, and cultivate limited quantities of marijuana.<ref name='LeafbuyerFrequently18'>{{cite web short |url=https://www.leafbuyer.com/alaska |title=Frequently Asked Questions About Marijuana in Alaska |date=25 May 2018 |accessdate=14 September 2018}}</ref><br />
<br />
The law does not provide guidance or regulation related to the legal opening and operation of marijuana dispensaries within the state. With the approval of adult-use of marijuana, effective 2016, new regulatory structures were codified that cover all aspects of the marijuana industry in Alaska. Medical and retail marijuana now share a common set of regulations, including those for inventory tracking and laboratory testing.<ref name='LeafbuyerFrequently18'></ref><br />
<br />
==Licensing requirements==<br />
Alaska defines four types of marijuana establishments: retail marijuana store, marijuana cultivation facilities, marijuana product manufacturing facilities, and marijuana testing facilities. All establishments must be licensed by the Marijuana Control Board, and each of the four types has its own license.<br />
<br />
===Marijuana testing facilities===<br />
A person or organization may not offer or provide marijuana testing services or results unless they have applied for and obtained a Marijuana Testing Facility license. There is an initial application that is common to all establishments, followed by a supplemental application for the specific type of facility. Testing facility icensing requirements do not apply to a licensed marijuana establishment that conducts in-house testing using its own equipment to test material produced within the same facility.<br />
<br />
====Conflict of interest====<br />
The code specifically states that a holder of a marijuana testing facility license may not hold another type of marijuana license in Alaska. Further, the licensee, or any employee or agent of the licensed testing facility are prohibited from having an ownership interest or direct or indirect financial interest in another licensed marijuana establishment within the state. Finally, the licensee may not have a financial interest in common with a person who holds a license in Alaska for a marijuana establishment other than a testing facility.<br />
<br />
<br />
====Privileges and prohibitions====<br />
Licensed marijuana testing facilities may have any amount of marijuana/products on premises at any given time as long as facility inventory tracking system used and indicates all marijuana on site is for testing purposes. However, distribution, sale, or transfer of marijuana directly to a consumer is prohibited, as is consumption of marijuana by anyone while on the premises of the testing facility.<br />
<br />
===SOP requirements===<br />
Testing facilities must have a written manual of standard operating procedures (SOPs) on site and available to all employees at all times. It must provide detailed instructions on how to perform each testing method the facility uses, as well as the minimum standards for each test. The SOP manual must cover:<br />
* Sample preparation for each matrix that will be tested<br />
<br />
* Reagent, solution, and reference standard preparation<br />
<br />
* Instrument setup, if applicable<br />
<br />
* Data acquisition<br />
<br />
* Calculation of results<br />
<br />
* Identification criteria<br />
<br />
* Quality control frequency<br />
<br />
* Quality control acceptance criteria<br />
<br />
* Corrective action protocols<br />
<br />
<br />
Personnel qualifications<br />
====Scientific director==== <br />
(3 AAC 306.630. Scientific director)<br />
LMTFs must employ a scientific director who is responsible for managing and directing laboratory operations within the testing facility; the scientific director will also be responsible for supervising all staff at the facility, and ensuring the work done in the laboratory meets required quality standards. The person filling this role must meet minimum education/experience qualifications by holding:<br />
<br />
* A doctorate degree in chemical or biological sciences with at least two years post-degree lab experience, or<br />
<br />
* A master's degree in chemical or biological sciences with at least four years post-degree lab experience, or<br />
<br />
* A bachelor's degree in chemical or biological sciences with at least six years post-degree lab experience<br />
<br />
====Marijuana handler permit====<br />
Per the general operating requirements for all marijuana establishments (3 AAC 306.700. "Article 7"), all licensees, employees, agents of a licensed marijuana establishment who sell, cultivate, manufacture, test, or transport marijuana in any form, or who check identification of consumers or visitors, must apply for and obtain a marijuana handler permit prior to beginning employment at the establishment. <br />
<br />
Applicants must first complete an education course approved by the Marijuana Control Board that addresses topics such as the statutory law and codes governing the marijuana industry in Alaska; the effects of consumption of marijuana; identifying a person who is impaired by marijuana consumption; how to determine valid identification; how to intervene to prevent unlawful marijuana consumption; and the penalties for unlawful acts by a licensee, an employee, or agent of a marijuana establishment. After completing the course, applicants must demonstrate they understand the material by passing a written test. A permit is then issued as long as the person meets certain criteria for a criminal background check. 3 AAC 306.700.(f) (Marijuana handler permit - DQs)<br />
<br />
Handling permits must be in the holder's immediate possession or a valid copy on file in the testing facility at all times when on the premises. Permits may be renewed every three years upon passing another written exam. <br />
<br />
6. Testing Required<br />
<br />
===Physical Plant Reqs===<br />
3 AAC 306.715. Security alarm systems and lock standards<br />
3 AAC 306.720. Video surveillance<br />
<br />
== References ==<br />
{{Reflist}}</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Alaska&diff=34005User:Rthiggins/StateCannabisTestingRegulations/Alaska2018-09-16T20:35:04Z<p>Rthiggins: Marijuana handler section</p>
<hr />
<div><br />
==Regulatory scheme==<br />
Medical use of marijuana was legalized in Alaska after the 1998 election. The law allows certified physicians to recommend treatment with medical marijuana to their patients with qualifying debilitating diseases. Patients must register with the state, and thereafter may legally possess, use, and cultivate limited quantities of marijuana.<ref name='LeafbuyerFrequently18'>{{cite web short |url=https://www.leafbuyer.com/alaska |title=Frequently Asked Questions About Marijuana in Alaska |date=25 May 2018 |accessdate=14 September 2018}}</ref><br />
<br />
The law does not provide guidance or regulation related to the legal opening and operation of marijuana dispensaries within the state. With the approval of adult-use of marijuana, effective 2016, new regulatory structures were codified that cover all aspects of the marijuana industry in Alaska. Medical and retail marijuana now share a common set of regulations, including those for inventory tracking and laboratory testing.<ref name='LeafbuyerFrequently18'></ref><br />
<br />
==Licensing requirements==<br />
Alaska defines four types of marijuana establishments: retail marijuana store, marijuana cultivation facilities, marijuana product manufacturing facilities, and marijuana testing facilities. All establishments must be licensed by the Marijuana Control Board, and each of the four types has its own license.<br />
<br />
===Marijuana testing facilities===<br />
A person or organization may not offer or provide marijuana testing services or results unless they have applied for and obtained a Marijuana Testing Facility license. There is an initial application that is common to all establishments, followed by a supplemental application for the specific type of facility. Testing facility icensing requirements do not apply to a licensed marijuana establishment that conducts in-house testing using its own equipment to test material produced within the same facility.<br />
<br />
====Conflict of interest====<br />
The code specifically states that a holder of a marijuana testing facility license may not hold another type of marijuana license in Alaska. Further, the licensee, or any employee or agent of the licensed testing facility are prohibited from having an ownership interest or direct or indirect financial interest in another licensed marijuana establishment within the state. Finally, the licensee may not have a financial interest in common with a person who holds a license in Alaska for a marijuana establishment other than a testing facility.<br />
<br />
<br />
====Privileges and prohibitions====<br />
Licensed marijuana testing facilities may have any amount of marijuana/products on premises at any given time as long as facility inventory tracking system used and indicates all marijuana on site is for testing purposes. However, distribution, sale, or transfer of marijuana directly to a consumer is prohibited, as is consumption of marijuana by anyone while on the premises of the testing facility.<br />
<br />
===SOP requirements===<br />
Testing facilities must have a written manual of standard operating procedures (SOPs) on site and available to all employees at all times. It must provide detailed instructions on how to perform each testing method the facility uses, as well as the minimum standards for each test. The SOP manual must cover:<br />
* Sample preparation for each matrix that will be tested<br />
<br />
* Reagent, solution, and reference standard preparation<br />
<br />
* Instrument setup, if applicable<br />
<br />
* Data acquisition<br />
<br />
* Calculation of results<br />
<br />
* Identification criteria<br />
<br />
* Quality control frequency<br />
<br />
* Quality control acceptance criteria<br />
<br />
* Corrective action protocols<br />
<br />
<br />
Personnel qualifications<br />
====Scientific director==== <br />
(3 AAC 306.630. Scientific director)<br />
LMTFs must employ a scientific director who is responsible for managing and directing laboratory operations within the testing facility; the scientific director will also be responsible for supervising all staff at the facility, and ensuring the work done in the laboratory meets required quality standards. The person filling this role must meet minimum education/experience qualifications by holding:<br />
<br />
* A doctorate degree in chemical or biological sciences with at least two years post-degree lab experience, or<br />
<br />
* A master's degree in chemical or biological sciences with at least four years post-degree lab experience, or<br />
<br />
* A bachelor's degree in chemical or biological sciences with at least six years post-degree lab experience<br />
<br />
====Marijuana handler permit====<br />
Per the general operating requirements for all marijuana establishments (3 AAC 306.700. "Article 7"), all licensees, employees, agents of a licensed marijuana establishment who sell, cultivate, manufacture, test, or transport marijuana in any form, or who check identification of consumers or visitors, must apply for and obtain a marijuana handler permit prior to beginning employment at the establishment. <br />
<br />
Applicants must first complete an education course approved by the Marijuana Control Board that addresses topics such as the statutory law and codes governing the marijuana industry in Alaska; the effects of consumption of marijuana; identifying a person who is impaired by marijuana consumption; how to determine valid identification; how to intervene to prevent unlawful marijuana consumption; and the penalties for unlawful acts by a licensee, an employee, or agent of a marijuana establishment. <br />
<br />
After completing the course, applicants must demonstrate they understand the material by passing a written test. A permit is then issued as long as the person meets certain criteria for a criminal background check. 3 AAC 306.700.(f) (Marijuana handler permit - DQs)<br />
<br />
6. Testing Required<br />
<br />
===Physical Plant Reqs===<br />
3 AAC 306.715. Security alarm systems and lock standards<br />
3 AAC 306.720. Video surveillance<br />
<br />
== References ==<br />
{{Reflist}}</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Alaska&diff=34004User:Rthiggins/StateCannabisTestingRegulations/Alaska2018-09-16T16:15:57Z<p>Rthiggins: Added SOP requirements section</p>
<hr />
<div><br />
==Regulatory scheme==<br />
Medical use of marijuana was legalized in Alaska after the 1998 election. The law allows certified physicians to recommend treatment with medical marijuana to their patients with qualifying debilitating diseases. Patients must register with the state, and thereafter may legally possess, use, and cultivate limited quantities of marijuana.<ref name='LeafbuyerFrequently18'>{{cite web short |url=https://www.leafbuyer.com/alaska |title=Frequently Asked Questions About Marijuana in Alaska |date=25 May 2018 |accessdate=14 September 2018}}</ref><br />
<br />
The law does not provide guidance or regulation related to the legal opening and operation of marijuana dispensaries within the state. With the approval of adult-use of marijuana, effective 2016, new regulatory structures were codified that cover all aspects of the marijuana industry in Alaska. Medical and retail marijuana now share a common set of regulations, including those for inventory tracking and laboratory testing.<ref name='LeafbuyerFrequently18'></ref><br />
<br />
==Licensing requirements==<br />
Alaska defines four types of marijuana establishments: retail marijuana store, marijuana cultivation facilities, marijuana product manufacturing facilities, and marijuana testing facilities. All establishments must be licensed by the Marijuana Control Board, and each of the four types has its own license.<br />
<br />
===Marijuana testing facilities===<br />
A person or organization may not offer or provide marijuana testing services or results unless they have applied for and obtained a Marijuana Testing Facility license. There is an initial application that is common to all establishments, followed by a supplemental application for the specific type of facility. Testing facility icensing requirements do not apply to a licensed marijuana establishment that conducts in-house testing using its own equipment to test material produced within the same facility.<br />
<br />
====Conflict of interest====<br />
The code specifically states that a holder of a marijuana testing facility license may not hold another type of marijuana license in Alaska. Further, the licensee, or any employee or agent of the licensed testing facility are prohibited from having an ownership interest or direct or indirect financial interest in another licensed marijuana establishment within the state. Finally, the licensee may not have a financial interest in common with a person who holds a license in Alaska for a marijuana establishment other than a testing facility.<br />
<br />
<br />
====Privileges and prohibitions====<br />
Licensed marijuana testing facilities may have any amount of marijuana/products on premises at any given time as long as facility inventory tracking system used and indicates all marijuana on site is for testing purposes. However, distribution, sale, or transfer of marijuana directly to a consumer is prohibited, as is consumption of marijuana by anyone while on the premises of the testing facility.<br />
<br />
====SOP requirements====<br />
Testing facilities must have a written manual of standard operating procedures (SOPs) on site and available to all employees at all times. It must provide detailed instructions on how to perform each testing method the facility uses, as well as the minimum standards for each test. The SOP manual must cover<br />
* Sample preparation for each matrix that will be tested;<br />
<br />
* Reagent, solution, and reference standard preparation;<br />
* Instrument setup, if applicable;<br />
* Standardization of volumetric reagent solutions, if applicable;<br />
* Data acquisition;<br />
* Calculation of results;<br />
* Identification criteria<br />
* Quality control frequency<br />
* Quality control acceptance criteria<br />
* Corrective action protocols<br />
<br />
<br />
<br />
5. Personnel qualifications<br />
6. Testing Required<br />
<br />
<br />
== References ==<br />
{{Reflist}}</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34003User:Rthiggins/StateCannabisTestingRegulations2018-09-16T12:30:32Z<p>Rthiggins: </p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
# Legal status of cannabis <br />
# Regulatory Authority<br />
# Regulatory scheme and titles of applicable statutes/codes<br />
# Testing facility licensing/registration requirements<br />
# Testing facility physical plant requirements (include security requirements here)<br />
# Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795<br />
# Personnel Requirements, Qualifications, Registration/Licensure<br />
# Inventory Tracking and handling of samples received by lab for testing<br />
# Sampling for testing requirements/methods<br />
# Products that require testing<br />
# Specific required tests for each product type<br />
# Required method for conducting required tests<br />
# Method validation, if no method is mandated and the lab develops its own testing method<br />
# Reporting results of testing (who, what, where, when, how)<br />
# QA/QC requirements<br />
# Record keeping requirements<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34002User:Rthiggins/StateCannabisTestingRegulations2018-09-16T12:29:30Z<p>Rthiggins: Added general info template for each state</p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
==General information template for each state==<br />
# Legal status of cannabis <br />
# Regulatory Authority<br />
# Regulatory scheme and titles of applicable statutes/codes<br />
# Testing facility licensing/registration requirements<br />
# Testing facility physical plant requirements (include security requirements here)<br />
# Laboratory Practices and SOP requirements (or reference to guidelines or authorities the state law indicates labs must follow, e.g. USP 795<br />
# Personnel Requirements, Qualifications, Registration/Licensure<br />
# Inventory Tracking and handling of samples received by lab for testing<br />
# Sampling for testing requirements/methods<br />
# Products that require testing<br />
# Specific required tests for each product type<br />
# Required method for conducting required tests<br />
# Method validation, if no method is mandated and the lab develops its own testing method<br />
# Reporting results of testing (who, what, where, when, how)<br />
# QA/QC requirements<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations/Alaska&diff=34001User:Rthiggins/StateCannabisTestingRegulations/Alaska2018-09-15T14:41:20Z<p>Rthiggins: Transferred content from previous page</p>
<hr />
<div><br />
==Regulatory scheme==<br />
Medical use of marijuana was legalized in Alaska after the 1998 election. The law allows certified physicians to recommend treatment with medical marijuana to their patients with qualifying debilitating diseases. Patients must register with the state, and thereafter may legally possess, use, and cultivate limited quantities of marijuana.<ref name='LeafbuyerFrequently18'>{{cite web short |url=https://www.leafbuyer.com/alaska |title=Frequently Asked Questions About Marijuana in Alaska |date=25 May 2018 |accessdate=14 September 2018}}</ref><br />
<br />
The law does not provide guidance or regulation related to the legal opening and operation of marijuana dispensaries within the state. With the approval of adult-use of marijuana, effective 2016, new regulatory structures were codified that cover all aspects of the marijuana industry in Alaska. Medical and retail marijuana now share a common set of regulations, including those for inventory tracking and laboratory testing.<ref name='LeafbuyerFrequently18'></ref><br />
<br />
==Licensing requirements==<br />
Alaska defines four types of marijuana establishments: retail marijuana store, marijuana cultivation facilities, marijuana product manufacturing facilities, and marijuana testing facilities. All establishments must be licensed by the Marijuana Control Board, and each of the four types has its own license.<br />
<br />
===Marijuana testing facilities===<br />
A person or organization may not offer or provide marijuana testing services or results unless they have applied for and obtained a Marijuana Testing Facility license. There is an initial application that is common to all establishments, followed by a supplemental application for the specific type of facility. Testing facility icensing requirements do not apply to a licensed marijuana establishment that conducts in-house testing using its own equipment to test material produced within the same facility.<br />
<br />
====Conflict of interest====<br />
The code specifically states that a holder of a marijuana testing facility license may not hold another type of marijuana license in Alaska. Further, the licensee, or any employee or agent of the licensed testing facility are prohibited from having an ownership interest or direct or indirect financial interest in another licensed marijuana establishment within the state. Finally, the licensee may not have a financial interest in common with a person who holds a license in Alaska for a marijuana establishment other than a testing facility.<br />
<br />
<br />
====Privileges and prohibitions====<br />
Licensed marijuana testing facilities may have any amount of marijuana/products on premises at any given time as long as facility inventory tracking system used and indicates all marijuana on site is for testing purposes. However, distribution, sale, or transfer of marijuana directly to a consumer is prohibited, as is consumption of marijuana by anyone while on the premises of the testing facility.<br />
<br />
====SOP requirements====<br />
5. Personnel qualifications<br />
6. Testing Required<br />
<br />
<br />
== References ==<br />
{{Reflist}}</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=34000User:Rthiggins/StateCannabisTestingRegulations2018-09-15T14:39:59Z<p>Rthiggins: Added Alaska page</p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.<br />
<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations/Alaska | Alaska]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins&diff=33999User:Rthiggins2018-09-15T14:34:39Z<p>Rthiggins: Added state regulations link</p>
<hr />
<div>Hello world, this is my user page.<br />
<br />
[[User:Rthiggins/Sandbox | Sandbox (official)]]<br />
<br />
[[User:Rthiggins/sandbox | sandbox (underground/actual experimental space)]]<br />
<br />
[[User:Rthiggins/MediaWikiTraining | MediaWiki Training Progress]]<br />
<br />
[[User:Rthiggins/StateCannabisTestingRegulations | State Testing Regulations Hub]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/StateCannabisTestingRegulations&diff=33998User:Rthiggins/StateCannabisTestingRegulations2018-09-15T14:32:57Z<p>Rthiggins: Created page with "This page will act as an information hub for the cannabis QA/QC state regulations update."</p>
<hr />
<div>This page will act as an information hub for the cannabis QA/QC state regulations update.</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Cannabis_Testing_Requirements&diff=33992User:Rthiggins/Cannabis Testing Requirements2018-09-14T04:44:48Z<p>Rthiggins: Set up section headings</p>
<hr />
<div>This page is the main hub of information on cannabis laboratory testing requirements in the United States. It is organized by state, each having its own subpage with detailed legal and regulatory information.<br />
<br />
<h2>States that only permit medical cannabis</h2> <br />
[[AlaskaCannaTestRegs | Alaska]]<br />
<br />
<br />
<h2>States that permit both medical and recreational cannabis</h2><br />
<br />
<h2>States without legal cannabis of any kind</h2></div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Cannabis_Testing_Requirements&diff=33991User:Rthiggins/Cannabis Testing Requirements2018-09-14T04:42:59Z<p>Rthiggins: Corrected Alaska link</p>
<hr />
<div>This page is the main hub of information on cannabis laboratory testing requirements in the United States. It is organized by state, each having its own subpage with detailed legal and regulatory information.<br />
<br />
<h2>States that only permit medical cannabis <br />
[[AlaskaCannaTestRegs | Alaska]]<br />
<br />
<br />
States that permit both medical and recreational cannabis<br />
<br />
States without legal cannabis of any kind</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Cannabis_Testing_Requirements&diff=33990User:Rthiggins/Cannabis Testing Requirements2018-09-14T04:40:15Z<p>Rthiggins: </p>
<hr />
<div>This page is the main hub of information on cannabis laboratory testing requirements in the United States. It is organized by state, each having its own subpage with detailed legal and regulatory information.<br />
<br />
States that only permit medical cannabis <br />
[[AlaskaCannaTestRegs | Alaska]]<br />
States that permit both medical and recreational cannabis<br />
<br />
States without legal cannabis of any kind</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Cannabis_Testing_Requirements&diff=33989User:Rthiggins/Cannabis Testing Requirements2018-09-14T04:39:38Z<p>Rthiggins: Created page and added content</p>
<hr />
<div>This page is the main hub of information on cannabis laboratory testing requirements in the United States. It is organized by state, each having its own subpage with detailed legal and regulatory information.<br />
<br />
States that only permit medical cannabis <br />
[[AlaskaCannaTestRegs Alaska]]<br />
States that permit both medical and recreational cannabis<br />
<br />
States without legal cannabis of any kind</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33988User:Rthiggins/Sandbox2018-09-14T04:22:28Z<p>Rthiggins: Added commas to citation formatting</p>
<hr />
<div>{{ombox<br />
| type = notice<br />
| image =<br />
| style = width960px;<br />
| text = All the writing on this page is original copy I wrote, except quotations and the definitions of pharmacology and medicinal chemistry, which are paraphrased from their respective Wikipedia articles.<br />
}}<br />
<br />
<br />
This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref name="VallanceTheFuture06">{{cite journal |authors=Vallance, P.; Smart, T.G. |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 |issue=S1|pages=S304–7 |year=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.<br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. <br />
[[File:Aldose reductase 1us0.png | thumb | border | sub | Aldose reductase: Not the sweetest enzyme]]<br />
<br />
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#000000;"| Table 27.1 Strict vs. Loose Serum Glucose Control<ref name="ReichardTheEffect93">{{cite journal |authors=Reichard, P.; Nilsson, B.Y.; Rosenqvist, U.|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |year=1993 |}}</ref><br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.<ref name="WilliamsFoyesPrinciples02">{{cite book |url= |chapter=Chapter 27: Insulin and Oral Hypoglycemic Drugs |title=Foye's Principles of Medicinal Chemistry |author=Williams, D.A.; Lemke, T.L. |pages=632 |publisher=Lippincott Williams & Wilkins |year=2002 |edition=5th |volume= |isbn=9780683307375 |accessdate=}}</ref></blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/><br />
<br />
<!---Place all category tags here--><br />
[[Category:User sandbox]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User_talk:Shawndouglas&diff=33982User talk:Shawndouglas2018-09-06T13:04:35Z<p>Rthiggins: /* Beginner exercise completed */ Moved link to User:Rthiggins/Sandbox to advanced training comment</p>
<hr />
<div>This is my talk page. Feel free to comment here if you have questions, suggestions, or need help.<br />
<br />
Simply start a topic by clicking "edit" on this talk page and copy/pasting this material in:<br />
<br />
<pre><br />
==Title of discussion==<br />
<br />
Your discussion<br />
</pre><br />
<br />
Replace "Title of discussion" with your discussion title and "Your discussion" with what you want to say.<br />
<br />
Also, don't forget to sign your post with four tildas like this:<br />
<br />
<pre>~~~~</pre><br />
<br />
Finally, if you are replying to an existing comment, please use the colon (:) in front of your comment, multiple for each further level. Example:<br />
<br />
<br />
<pre><br />
<br />
==Great job on the Laboratory article==<br />
Just wanted to give you kudos for the well-researched article! Keep at it. Joeuser 19:22, 10 February 2011 (EST)<br />
<br />
: Thanks so much! I hope to add more content to the article as time allows. Let me know if I'm missing anything. Janeuser 12:12, 11 February 2011 (EST)<br />
<br />
:: No, I don't see any glaring omissions. I'll watch the article though in case someone else gets crazy with the edits. ~~~~<br />
</pre><br />
==eLabFTW==<br />
<br />
Hello, I added references as requested. The Paris Open Source Summit link doesn't show much for some reason right now, I guess they have a problem; but on this page there is a scheduled talk about this fork by INRIA.<br />
<br />
[[User:NicolasCARPi|NicolasCARPi]] ([[User talk:NicolasCARPi|talk]]) 16:38, 13 October 2016 (UTC)<br />
<br />
==Sponsor Logo Link Broken==<br />
Hi, <br />
The Autoscribe Informatics sponsor logo on the LHS on the top level pages has a broken link.<br />
It should connect to the Autoscribe Ltd. Page<br />
<br />
Also since we have change become much more international we are now known as Autoscribe Informatics not Autoscribe Ltd. Would you be able to help me move the page to "Autoscribe Informatics" and redirect "Autoscribe Ltd." and "Autoscribe Ltd" to "Autoscribe Informatics"<br />
<br />
Thanks,<br />
<br />
Tim<br />
[[User:Tim.daniels|Tim.daniels]] ([[User talk:Tim.daniels|talk]]) 15:02, 10 October 2016 (UTC)<br />
==Updating Sponsor Logo==<br />
<br />
Hi Shawn,<br />
Would you be able to update the Autoscribe Informatics logo on the LHS column please? I've updated the one on the Autoscribe Informatics page but cannot get to the sponsors logos to update that. Thanks Tim.<br />
<br />
[[User:Tim.daniels|Tim.daniels]] ([[User talk:Tim.daniels|talk]]) 13:13, 22 October 2015 (UTC)<br />
<br />
==Thank you!==<br />
<br />
Thanks Shawn and everybody for all the work and contributions so far. <br />
I'm getting value out of the wiki already and am looking forward to more complete content. <br />
There is some great information here so far and the wiki is looking very promising. <br />
I wasn't aware of many of the wiki standards when I started posting, so have posted a lot of non-standard content, but I'm going back and cleaning them up and now I know better when adding new content.<br />
<br />
[[User:Andersjim|Jim Anderson]] 11:08, 12 May 2011 (EDT)<br />
<br />
==Wiki practice==<br />
The wiki practice session is finished. Thanks. [[User:Jdelartigue|Jdelartigue]] 19:08, 22 February 2012 (EST)<br />
<br />
==Embedding HTML==<br />
<br />
There are some neat Youtube videos that I'd like to embed on the chemical industry page. What do you think about turning on the raw html feature? Too risky from a security perspective?<br />
<br />
[[User:Jleecbd|Jleecbd]] 11:00, 9 April 2012 (EDT)<br />
<br />
: I sent a message to John about embedding video in the wiki, specifically in regards to an [http://www.mediawiki.org/wiki/Extension:EmbedVideo EmbedVideo extension]. However, he indicated that the security concerns were enough for him to rather go with links to videos. (This was in context to the [[:Category:Open-source software|open-source software]] articles I was working on.) I assume a similar suggestion to John about opening up [http://www.mediawiki.org/wiki/Manual:$wgRawHtml HTML] would result in the same response. There seems to be a more [http://www.mediawiki.org/wiki/Extension:Secure_HTML secure option] involving hashes and secret keys. That's a little out of my league, but it could be an option if you feel embedding video via HTML would truly enhance the article. Feel free to point John to this extension if you think it's worth a look.<br />
:<br />
: [[User:Shawndouglas|Shawn Douglas]] 14:13, 9 April 2012 (EDT)<br />
<br />
==Completed My First Entry!==<br />
I just wanted to tell you, that it seems that my wiki entry is completed on my sandbox. <br />
<br />
Let me know if it's wrong, I think it is done to the specifications listed [[User:RebeccaFein|RebeccaFein]] 16:17, 3 February 2013 (EST)<br />
<br />
==Updating Pages related to my company Lab-Ally==<br />
<br />
<br />
I am finally getting around to some substantial editing and creation of pages on LIMSWiki that will add new information or correct outdated or inaccurate information related to Lab-Ally, Rescentris, CERF ELN and RSpace ELN. I’m performing these edits under the username “invasifspecies”. I don’t have the slightest interest in contributing anything other than well sourced, accurate information using language that is as neutral and “spin free” as possible. You are welcome to look at any of my edits and call me out on anything that you think is not stylistically compatible with your guidelines. <br />
<br />
The Lab-Ally company page is:<br />
<br />
http://www.limswiki.org/index.php/Lab-Ally_LLC<br />
<br />
I made some edits there December 19th 2016, let me know if you think any of them are inappropriate. I will soon be making pages for CERF ELN RSpace ELN and eCAT. Naturally I will make them as objective as I can. <br />
<br />
I note that the page:<br />
<br />
http://www.limswiki.org/index.php/Inactive_vendor<br />
<br />
has been protected. Unfortunately I see a number of errors there. There is a typo that is preventing the Lab-Ally link from working. There is an extra period in the company name link. See below:<br />
<br />
Rescentris, Inc. CERF United States Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Rescentris entry for more history.<br />
<br />
Since Rescentris is also now defunct and presumably their entry will no longer be updated, I would request changing:<br />
<br />
"Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Rescentris entry for more history.” <br />
<br />
to <br />
<br />
"Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Lab-Ally LLC entry for more history.” <br />
<br />
<br />
Also, the now defunct “irisnote” is missing from this list, but it should be added. See:<br />
<br />
http://www.limswiki.org/index.php/Irisnote,_Inc.<br />
<br />
More information about Lab-Ally and CERF ELN are available at lab-ally.com and cerf-notebook.com<br />
<br />
Regards,<br />
<br />
rjday@lab-ally.com<br />
<br />
[[User:Invasifspecies|Invasifspecies]] ([[User talk:Invasifspecies|talk]]) 00:48, 20 December 2016 (UTC)<br />
<br />
<pre><br />
==email==<br />
<br />
hello Shawn, I sent you an email. Just letting you know, in case you don't check the mail that frequently.<br />
kind regards, Elisabeth<br />
</pre><br />
<pre>~~~~</pre><br />
<br />
==Beginner exercise completed==<br />
I think this is up to snuff, or close. Your tutorial was Grade A outrageously helpful. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 16:46, 2 September 2018 (UTC)<br />
<br />
Intermediate exercise completed. -- [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 12:42, 4 September 2018 (UTC)<br />
: Reviewed, and feedback emailed. Good work! [[User:Shawndouglas|Shawn Douglas]] ([[User talk:Shawndouglas|talk]]) 19:08, 4 September 2018 (UTC)<br />
:: Many thanks, I've implemented the suggestions you made. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 13:02, 6 September 2018 (UTC)<br />
<br />
Advanced exercise completed, available [[User:Rthiggins/Sandbox | here]]. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 13:03, 6 September 2018 (UTC)</div>Rthigginshttps://www.limswiki.org/index.php?title=User_talk:Shawndouglas&diff=33981User talk:Shawndouglas2018-09-06T13:03:04Z<p>Rthiggins: /* Beginner exercise completed */</p>
<hr />
<div>This is my talk page. Feel free to comment here if you have questions, suggestions, or need help.<br />
<br />
Simply start a topic by clicking "edit" on this talk page and copy/pasting this material in:<br />
<br />
<pre><br />
==Title of discussion==<br />
<br />
Your discussion<br />
</pre><br />
<br />
Replace "Title of discussion" with your discussion title and "Your discussion" with what you want to say.<br />
<br />
Also, don't forget to sign your post with four tildas like this:<br />
<br />
<pre>~~~~</pre><br />
<br />
Finally, if you are replying to an existing comment, please use the colon (:) in front of your comment, multiple for each further level. Example:<br />
<br />
<br />
<pre><br />
<br />
==Great job on the Laboratory article==<br />
Just wanted to give you kudos for the well-researched article! Keep at it. Joeuser 19:22, 10 February 2011 (EST)<br />
<br />
: Thanks so much! I hope to add more content to the article as time allows. Let me know if I'm missing anything. Janeuser 12:12, 11 February 2011 (EST)<br />
<br />
:: No, I don't see any glaring omissions. I'll watch the article though in case someone else gets crazy with the edits. ~~~~<br />
</pre><br />
==eLabFTW==<br />
<br />
Hello, I added references as requested. The Paris Open Source Summit link doesn't show much for some reason right now, I guess they have a problem; but on this page there is a scheduled talk about this fork by INRIA.<br />
<br />
[[User:NicolasCARPi|NicolasCARPi]] ([[User talk:NicolasCARPi|talk]]) 16:38, 13 October 2016 (UTC)<br />
<br />
==Sponsor Logo Link Broken==<br />
Hi, <br />
The Autoscribe Informatics sponsor logo on the LHS on the top level pages has a broken link.<br />
It should connect to the Autoscribe Ltd. Page<br />
<br />
Also since we have change become much more international we are now known as Autoscribe Informatics not Autoscribe Ltd. Would you be able to help me move the page to "Autoscribe Informatics" and redirect "Autoscribe Ltd." and "Autoscribe Ltd" to "Autoscribe Informatics"<br />
<br />
Thanks,<br />
<br />
Tim<br />
[[User:Tim.daniels|Tim.daniels]] ([[User talk:Tim.daniels|talk]]) 15:02, 10 October 2016 (UTC)<br />
==Updating Sponsor Logo==<br />
<br />
Hi Shawn,<br />
Would you be able to update the Autoscribe Informatics logo on the LHS column please? I've updated the one on the Autoscribe Informatics page but cannot get to the sponsors logos to update that. Thanks Tim.<br />
<br />
[[User:Tim.daniels|Tim.daniels]] ([[User talk:Tim.daniels|talk]]) 13:13, 22 October 2015 (UTC)<br />
<br />
==Thank you!==<br />
<br />
Thanks Shawn and everybody for all the work and contributions so far. <br />
I'm getting value out of the wiki already and am looking forward to more complete content. <br />
There is some great information here so far and the wiki is looking very promising. <br />
I wasn't aware of many of the wiki standards when I started posting, so have posted a lot of non-standard content, but I'm going back and cleaning them up and now I know better when adding new content.<br />
<br />
[[User:Andersjim|Jim Anderson]] 11:08, 12 May 2011 (EDT)<br />
<br />
==Wiki practice==<br />
The wiki practice session is finished. Thanks. [[User:Jdelartigue|Jdelartigue]] 19:08, 22 February 2012 (EST)<br />
<br />
==Embedding HTML==<br />
<br />
There are some neat Youtube videos that I'd like to embed on the chemical industry page. What do you think about turning on the raw html feature? Too risky from a security perspective?<br />
<br />
[[User:Jleecbd|Jleecbd]] 11:00, 9 April 2012 (EDT)<br />
<br />
: I sent a message to John about embedding video in the wiki, specifically in regards to an [http://www.mediawiki.org/wiki/Extension:EmbedVideo EmbedVideo extension]. However, he indicated that the security concerns were enough for him to rather go with links to videos. (This was in context to the [[:Category:Open-source software|open-source software]] articles I was working on.) I assume a similar suggestion to John about opening up [http://www.mediawiki.org/wiki/Manual:$wgRawHtml HTML] would result in the same response. There seems to be a more [http://www.mediawiki.org/wiki/Extension:Secure_HTML secure option] involving hashes and secret keys. That's a little out of my league, but it could be an option if you feel embedding video via HTML would truly enhance the article. Feel free to point John to this extension if you think it's worth a look.<br />
:<br />
: [[User:Shawndouglas|Shawn Douglas]] 14:13, 9 April 2012 (EDT)<br />
<br />
==Completed My First Entry!==<br />
I just wanted to tell you, that it seems that my wiki entry is completed on my sandbox. <br />
<br />
Let me know if it's wrong, I think it is done to the specifications listed [[User:RebeccaFein|RebeccaFein]] 16:17, 3 February 2013 (EST)<br />
<br />
==Updating Pages related to my company Lab-Ally==<br />
<br />
<br />
I am finally getting around to some substantial editing and creation of pages on LIMSWiki that will add new information or correct outdated or inaccurate information related to Lab-Ally, Rescentris, CERF ELN and RSpace ELN. I’m performing these edits under the username “invasifspecies”. I don’t have the slightest interest in contributing anything other than well sourced, accurate information using language that is as neutral and “spin free” as possible. You are welcome to look at any of my edits and call me out on anything that you think is not stylistically compatible with your guidelines. <br />
<br />
The Lab-Ally company page is:<br />
<br />
http://www.limswiki.org/index.php/Lab-Ally_LLC<br />
<br />
I made some edits there December 19th 2016, let me know if you think any of them are inappropriate. I will soon be making pages for CERF ELN RSpace ELN and eCAT. Naturally I will make them as objective as I can. <br />
<br />
I note that the page:<br />
<br />
http://www.limswiki.org/index.php/Inactive_vendor<br />
<br />
has been protected. Unfortunately I see a number of errors there. There is a typo that is preventing the Lab-Ally link from working. There is an extra period in the company name link. See below:<br />
<br />
Rescentris, Inc. CERF United States Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Rescentris entry for more history.<br />
<br />
Since Rescentris is also now defunct and presumably their entry will no longer be updated, I would request changing:<br />
<br />
"Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Rescentris entry for more history.” <br />
<br />
to <br />
<br />
"Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Lab-Ally LLC entry for more history.” <br />
<br />
<br />
Also, the now defunct “irisnote” is missing from this list, but it should be added. See:<br />
<br />
http://www.limswiki.org/index.php/Irisnote,_Inc.<br />
<br />
More information about Lab-Ally and CERF ELN are available at lab-ally.com and cerf-notebook.com<br />
<br />
Regards,<br />
<br />
rjday@lab-ally.com<br />
<br />
[[User:Invasifspecies|Invasifspecies]] ([[User talk:Invasifspecies|talk]]) 00:48, 20 December 2016 (UTC)<br />
<br />
<pre><br />
==email==<br />
<br />
hello Shawn, I sent you an email. Just letting you know, in case you don't check the mail that frequently.<br />
kind regards, Elisabeth<br />
</pre><br />
<pre>~~~~</pre><br />
<br />
==Beginner exercise completed==<br />
I think this is up to snuff, or close. Your tutorial was Grade A outrageously helpful. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 16:46, 2 September 2018 (UTC)<br />
<br />
Intermediate exercise completed, available [[User:Rthiggins/Sandbox | here]]. -- [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 12:42, 4 September 2018 (UTC)<br />
: Reviewed, and feedback emailed. Good work! [[User:Shawndouglas|Shawn Douglas]] ([[User talk:Shawndouglas|talk]]) 19:08, 4 September 2018 (UTC)<br />
:: Many thanks, I've implemented the suggestions you made. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 13:02, 6 September 2018 (UTC)<br />
<br />
Advanced exercise completed. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 13:03, 6 September 2018 (UTC)</div>Rthigginshttps://www.limswiki.org/index.php?title=User_talk:Shawndouglas&diff=33980User talk:Shawndouglas2018-09-06T13:02:32Z<p>Rthiggins: /* Beginner exercise completed */</p>
<hr />
<div>This is my talk page. Feel free to comment here if you have questions, suggestions, or need help.<br />
<br />
Simply start a topic by clicking "edit" on this talk page and copy/pasting this material in:<br />
<br />
<pre><br />
==Title of discussion==<br />
<br />
Your discussion<br />
</pre><br />
<br />
Replace "Title of discussion" with your discussion title and "Your discussion" with what you want to say.<br />
<br />
Also, don't forget to sign your post with four tildas like this:<br />
<br />
<pre>~~~~</pre><br />
<br />
Finally, if you are replying to an existing comment, please use the colon (:) in front of your comment, multiple for each further level. Example:<br />
<br />
<br />
<pre><br />
<br />
==Great job on the Laboratory article==<br />
Just wanted to give you kudos for the well-researched article! Keep at it. Joeuser 19:22, 10 February 2011 (EST)<br />
<br />
: Thanks so much! I hope to add more content to the article as time allows. Let me know if I'm missing anything. Janeuser 12:12, 11 February 2011 (EST)<br />
<br />
:: No, I don't see any glaring omissions. I'll watch the article though in case someone else gets crazy with the edits. ~~~~<br />
</pre><br />
==eLabFTW==<br />
<br />
Hello, I added references as requested. The Paris Open Source Summit link doesn't show much for some reason right now, I guess they have a problem; but on this page there is a scheduled talk about this fork by INRIA.<br />
<br />
[[User:NicolasCARPi|NicolasCARPi]] ([[User talk:NicolasCARPi|talk]]) 16:38, 13 October 2016 (UTC)<br />
<br />
==Sponsor Logo Link Broken==<br />
Hi, <br />
The Autoscribe Informatics sponsor logo on the LHS on the top level pages has a broken link.<br />
It should connect to the Autoscribe Ltd. Page<br />
<br />
Also since we have change become much more international we are now known as Autoscribe Informatics not Autoscribe Ltd. Would you be able to help me move the page to "Autoscribe Informatics" and redirect "Autoscribe Ltd." and "Autoscribe Ltd" to "Autoscribe Informatics"<br />
<br />
Thanks,<br />
<br />
Tim<br />
[[User:Tim.daniels|Tim.daniels]] ([[User talk:Tim.daniels|talk]]) 15:02, 10 October 2016 (UTC)<br />
==Updating Sponsor Logo==<br />
<br />
Hi Shawn,<br />
Would you be able to update the Autoscribe Informatics logo on the LHS column please? I've updated the one on the Autoscribe Informatics page but cannot get to the sponsors logos to update that. Thanks Tim.<br />
<br />
[[User:Tim.daniels|Tim.daniels]] ([[User talk:Tim.daniels|talk]]) 13:13, 22 October 2015 (UTC)<br />
<br />
==Thank you!==<br />
<br />
Thanks Shawn and everybody for all the work and contributions so far. <br />
I'm getting value out of the wiki already and am looking forward to more complete content. <br />
There is some great information here so far and the wiki is looking very promising. <br />
I wasn't aware of many of the wiki standards when I started posting, so have posted a lot of non-standard content, but I'm going back and cleaning them up and now I know better when adding new content.<br />
<br />
[[User:Andersjim|Jim Anderson]] 11:08, 12 May 2011 (EDT)<br />
<br />
==Wiki practice==<br />
The wiki practice session is finished. Thanks. [[User:Jdelartigue|Jdelartigue]] 19:08, 22 February 2012 (EST)<br />
<br />
==Embedding HTML==<br />
<br />
There are some neat Youtube videos that I'd like to embed on the chemical industry page. What do you think about turning on the raw html feature? Too risky from a security perspective?<br />
<br />
[[User:Jleecbd|Jleecbd]] 11:00, 9 April 2012 (EDT)<br />
<br />
: I sent a message to John about embedding video in the wiki, specifically in regards to an [http://www.mediawiki.org/wiki/Extension:EmbedVideo EmbedVideo extension]. However, he indicated that the security concerns were enough for him to rather go with links to videos. (This was in context to the [[:Category:Open-source software|open-source software]] articles I was working on.) I assume a similar suggestion to John about opening up [http://www.mediawiki.org/wiki/Manual:$wgRawHtml HTML] would result in the same response. There seems to be a more [http://www.mediawiki.org/wiki/Extension:Secure_HTML secure option] involving hashes and secret keys. That's a little out of my league, but it could be an option if you feel embedding video via HTML would truly enhance the article. Feel free to point John to this extension if you think it's worth a look.<br />
:<br />
: [[User:Shawndouglas|Shawn Douglas]] 14:13, 9 April 2012 (EDT)<br />
<br />
==Completed My First Entry!==<br />
I just wanted to tell you, that it seems that my wiki entry is completed on my sandbox. <br />
<br />
Let me know if it's wrong, I think it is done to the specifications listed [[User:RebeccaFein|RebeccaFein]] 16:17, 3 February 2013 (EST)<br />
<br />
==Updating Pages related to my company Lab-Ally==<br />
<br />
<br />
I am finally getting around to some substantial editing and creation of pages on LIMSWiki that will add new information or correct outdated or inaccurate information related to Lab-Ally, Rescentris, CERF ELN and RSpace ELN. I’m performing these edits under the username “invasifspecies”. I don’t have the slightest interest in contributing anything other than well sourced, accurate information using language that is as neutral and “spin free” as possible. You are welcome to look at any of my edits and call me out on anything that you think is not stylistically compatible with your guidelines. <br />
<br />
The Lab-Ally company page is:<br />
<br />
http://www.limswiki.org/index.php/Lab-Ally_LLC<br />
<br />
I made some edits there December 19th 2016, let me know if you think any of them are inappropriate. I will soon be making pages for CERF ELN RSpace ELN and eCAT. Naturally I will make them as objective as I can. <br />
<br />
I note that the page:<br />
<br />
http://www.limswiki.org/index.php/Inactive_vendor<br />
<br />
has been protected. Unfortunately I see a number of errors there. There is a typo that is preventing the Lab-Ally link from working. There is an extra period in the company name link. See below:<br />
<br />
Rescentris, Inc. CERF United States Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Rescentris entry for more history.<br />
<br />
Since Rescentris is also now defunct and presumably their entry will no longer be updated, I would request changing:<br />
<br />
"Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Rescentris entry for more history.” <br />
<br />
to <br />
<br />
"Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Lab-Ally LLC entry for more history.” <br />
<br />
<br />
Also, the now defunct “irisnote” is missing from this list, but it should be added. See:<br />
<br />
http://www.limswiki.org/index.php/Irisnote,_Inc.<br />
<br />
More information about Lab-Ally and CERF ELN are available at lab-ally.com and cerf-notebook.com<br />
<br />
Regards,<br />
<br />
rjday@lab-ally.com<br />
<br />
[[User:Invasifspecies|Invasifspecies]] ([[User talk:Invasifspecies|talk]]) 00:48, 20 December 2016 (UTC)<br />
<br />
<pre><br />
==email==<br />
<br />
hello Shawn, I sent you an email. Just letting you know, in case you don't check the mail that frequently.<br />
kind regards, Elisabeth<br />
</pre><br />
<pre>~~~~</pre><br />
<br />
==Beginner exercise completed==<br />
I think this is up to snuff, or close. Your tutorial was Grade A outrageously helpful. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 16:46, 2 September 2018 (UTC)<br />
<br />
Intermediate exercise completed, available [[User:Rthiggins/Sandbox | here]]. -- [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 12:42, 4 September 2018 (UTC)<br />
: Reviewed, and feedback emailed. Good work! [[User:Shawndouglas|Shawn Douglas]] ([[User talk:Shawndouglas|talk]]) 19:08, 4 September 2018 (UTC)<br />
:: Many thanks, I've implemented the suggestions you made. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 13:02, 6 September 2018 (UTC)</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/MediaWikiTraining&diff=33979User:Rthiggins/MediaWikiTraining2018-09-06T12:58:16Z<p>Rthiggins: </p>
<hr />
<div>For a more granular look at what I've been practicing, please head over to '''[[User:Rthiggins/sandbox | sandbox (little s)]]''', which is less formal than the official '''[[User:Rthiggins/Sandbox | Sandbox (big S)]]''' developed as part of the training program.<br />
<br />
<br />
==Questions==<br />
===Pending questions===<br />
* Is there a difference between the <nowiki><del> and <strike></nowiki> tags, either in their actual effects or in the way they're used?<br />
* What is the purpose (if any) of all the additional attributes defined in the <nowiki><pre></nowiki> tag on the intermedate training page? I couldn't discern any differences between how it displays on the training page vs my experimental page where I just used <nowiki><pre></nowiki> without attributes.<br />
<br />
<br />
===Answered questions===<br />
;How does one define the image description attribute?<br />
: 1. Any text not recognized as an attribute value (e.g. 960px, baseline, thumb, etc) is interpreted as description text. If there is more than one unparsable (is that the right term?) string, the one that appears last will be used as the description.<br />
<br />
: 2. For example, <nowiki>[[Filename:Derek Zoolander.png|500px|Hansel|baseline|So hot right now]]</nowiki> would use "So hot right now" as the descriptive text, ignoring Hansel.<br />
<br />
: 3. In non-thumbnail images, the descriptive text shows up when mousing over the image. For images set as thumbnails, the description is displayed with the image as a caption.<br />
<br />
<br />
<br />
<br /><br />
==MediaWiki training tracker==<br />
====Beginner exercise====<br />
Well, it's time to practice everything you've learned here. Hopefully you haven't created your user page and user talk pages yet. If you have, you can still continue with this exercise, though skip the creation step listed at the beginning. <br />
<br />
<del>1. Create your user profile and user talk pages by clicking the red links as mentioned in [[Help:MediaWiki basics/Beginner training#User pages and functions|User pages and functions]]. Add an introductory line of text to each page and save them.</del><br />
<br />
<del>2. Next, add a subpage to your user page (as described in [[Help:MediaWiki basics/Beginner training#How to create a page|How to create a page]]) called Sandbox. Do this by first adding an internal link to your user page, saving it, and then clicking the associated red link that appears. Add an introductory line of text to the Sandbox subpage and save it. (Hint: if you still need help, use [[User:Shawndouglas]] as a guide.)</del><br />
<br />
<del>3. It's time to play in your sandbox! Let's add two paragraphs about your favorite subject in grade school or university. You need to include the following elements in this text:</del><br />
<br />
* <del>at least one main header</del><br />
* <del>at least one subheader</del><br />
* <del>an example of bold text</del><br />
* <del>an example of italicized text</del><br />
* <del>your choice of either a bulleted or numbered list</del><br />
* <del>one definition list</del><br />
* <del>at least two internal links (the page [[Special:AllPages]] may come in handy)</del><br />
* <del>at least two external links, with link text</del><br />
* <del>proper spacing</del><br />
<br />
<del>4. Go to your User talk: page and choose to watch it.</del><br />
<br />
<del>5. Go to your user preferences and make all of the suggested changes listed in the [[Help:MediaWiki basics/Beginner training#Preferences|Preferences]] section, including selecting the "Email me when a page or a file on my watchlist is changed" option.</del><br />
<br />
<del>6. Go to [[User talk:Shawndouglas]], select "edit", add a new header, and leave a comment stating you've completed the beginner exercise. Be sure to sign your comment!</del><br />
<br />
====Intermediate exercise====<br />
<br />
<strike>1. Open your sandbox for editing. Read over your previously written material concerning your favorite subject in grade school or university. We're going to modify this content a bit.<br />
<br />
2. After re-reading your content, think of what additional words, numbers, facts, multimedia, etc. you could add to your topic that would utilize what you learned from this training document. You may have to write a new paragraph, rearrange content, etc. See item three for the specifics of what you should be adding.<br />
<br />
3. Integrate the following items into your existing content, modifying the text and its organization as needed:<br />
<br />
* at least two examples of intermediate non-blockquote text formatting described on this page<br />
* at least one blockquote of text; preferably use a quote from a book, journal, or web page with content relevant to your topic (use [http://books.google.com/ Google Books], [http://scholar.google.com/ Google Scholar], etc. if you need help)<br />
* at least one relevant to semi-relevant image from [[commons:Main Page|Wikimedia Commons]] (WC); if you can't find such an image, choose the closest thing you can find from there<br />
* a table with at least a header row, two normal rows, and three normal columns; use the class "wikitable" and at least one example of <code>colspan=</code> or <code>rowspan=</code><br />
* (optional) a WC sound or video file if applicable to your topic<br />
<br />
4. Save your work. Also, ''note the exact source'' of the quote you pulled for this exercise. You're going to need that information for the [[Help:MediaWiki basics/Advanced training|advanced training]] exercise.<br />
<br />
5. Go to [[User talk:Shawndouglas]], select "edit", and under your original header you started from the beginner exercise leave a comment stating you've completed the intermediate exercise. Be sure to sign your comment!</strike><br />
<br />
<strike>1. Open your sandbox for editing. Read over your previously written material concerning your favorite subject in grade school or university. Again, we're going to supplement this material with what we've learned in this training session.<br />
<br />
2. After re-reading your content, think of how you can 1. use "Template:Ombox" effectively in your topic content and 2. apply citations to the text you've written. If your text is lacking in facts, add some information that would require a citation or two.<br />
<br />
3. Integrate the following items into your existing content, modifying the text and its organization as needed:<br />
* one <nowiki>{{ombox}}</nowiki> template, including the following parameters: type, image, style, and text<br />
* a section called "External links" (using a header) at the bottom, and under that a bulleted list of at least two external web links relating to your content (refer to the beginner training if you don't remember how to do this)<br />
* a "References" section at the bottom of the page (after "External links")<br />
* at least three unique citations using proper citation templates<br />
<br />
4. Remember that quote you added to your text in the intermediate training? You were asked to note the exact source of the quote. Well, now is the time to apply the correct citation template to that quote and populate it with the details of the source. Place the citation at the end of the quote, complete with a unique "ref name".<br />
<br />
5. Add your sandbox page to the category "User sandbox". Save your work<br />
<br />
6. Go to User talk:Shawndouglas, select "edit", and under your original header you started from the beginner exercise leave a comment stating you've completed the advanced exercise. Be sure to sign your comment!</strike></div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/MediaWikiTraining&diff=33978User:Rthiggins/MediaWikiTraining2018-09-06T12:53:44Z<p>Rthiggins: Added advanced exercise; crossed off items on intermediate and advanced exercises</p>
<hr />
<div>For a more granular look at what I've been practicing, please head over to '''[[User:Rthiggins/sandbox | sandbox (little s)]]''', which is less formal than the official '''[[User:Rthiggins/Sandbox | Sandbox (big S)]]''' developed as part of the training program.<br />
<br />
<br />
==Questions==<br />
===Pending questions===<br />
* Is there a difference between the <nowiki><del> and <strike></nowiki> tags, either in their actual effects or in the way they're used?<br />
* What is the purpose (if any) of all the additional attributes defined in the <nowiki><pre></nowiki> tag on the intermedate training page? I couldn't discern any differences between how it displays on the training page vs my experimental page where I just used <nowiki><pre></nowiki> without attributes.<br />
<br />
<br />
===Answered questions===<br />
;How does one define the image description attribute?<br />
: 1. Any text not recognized as an attribute value (e.g. 960px, baseline, thumb, etc) is interpreted as description text. If there is more than one unparsable (is that the right term?) string, the one that appears last will be used as the description.<br />
<br />
: 2. For example, <nowiki>[[Filename:Derek Zoolander.png|500px|Hansel|baseline|So hot right now]]</nowiki> would use "So hot right now" as the descriptive text, ignoring Hansel.<br />
<br />
: 3. In non-thumbnail images, the descriptive text shows up when mousing over the image. For images set as thumbnails, the description is displayed with the image as a caption.<br />
<br />
<br />
<br />
<br /><br />
==MediaWiki training tracker==<br />
====Beginner exercise====<br />
Well, it's time to practice everything you've learned here. Hopefully you haven't created your user page and user talk pages yet. If you have, you can still continue with this exercise, though skip the creation step listed at the beginning. <br />
<br />
<del>1. Create your user profile and user talk pages by clicking the red links as mentioned in [[Help:MediaWiki basics/Beginner training#User pages and functions|User pages and functions]]. Add an introductory line of text to each page and save them.</del><br />
<br />
<del>2. Next, add a subpage to your user page (as described in [[Help:MediaWiki basics/Beginner training#How to create a page|How to create a page]]) called Sandbox. Do this by first adding an internal link to your user page, saving it, and then clicking the associated red link that appears. Add an introductory line of text to the Sandbox subpage and save it. (Hint: if you still need help, use [[User:Shawndouglas]] as a guide.)</del><br />
<br />
<del>3. It's time to play in your sandbox! Let's add two paragraphs about your favorite subject in grade school or university. You need to include the following elements in this text:</del><br />
<br />
* <del>at least one main header</del><br />
* <del>at least one subheader</del><br />
* <del>an example of bold text</del><br />
* <del>an example of italicized text</del><br />
* <del>your choice of either a bulleted or numbered list</del><br />
* <del>one definition list</del><br />
* <del>at least two internal links (the page [[Special:AllPages]] may come in handy)</del><br />
* <del>at least two external links, with link text</del><br />
* <del>proper spacing</del><br />
<br />
<del>4. Go to your User talk: page and choose to watch it.</del><br />
<br />
<del>5. Go to your user preferences and make all of the suggested changes listed in the [[Help:MediaWiki basics/Beginner training#Preferences|Preferences]] section, including selecting the "Email me when a page or a file on my watchlist is changed" option.</del><br />
<br />
<del>6. Go to [[User talk:Shawndouglas]], select "edit", add a new header, and leave a comment stating you've completed the beginner exercise. Be sure to sign your comment!</del><br />
<br />
====Intermediate exercise====<br />
<br />
<strike>1. Open your sandbox for editing. Read over your previously written material concerning your favorite subject in grade school or university. We're going to modify this content a bit.<br />
<br />
2. After re-reading your content, think of what additional words, numbers, facts, multimedia, etc. you could add to your topic that would utilize what you learned from this training document. You may have to write a new paragraph, rearrange content, etc. See item three for the specifics of what you should be adding.<br />
<br />
3. Integrate the following items into your existing content, modifying the text and its organization as needed:<br />
<br />
* at least two examples of intermediate non-blockquote text formatting described on this page<br />
* at least one blockquote of text; preferably use a quote from a book, journal, or web page with content relevant to your topic (use [http://books.google.com/ Google Books], [http://scholar.google.com/ Google Scholar], etc. if you need help)<br />
* at least one relevant to semi-relevant image from [[commons:Main Page|Wikimedia Commons]] (WC); if you can't find such an image, choose the closest thing you can find from there<br />
* a table with at least a header row, two normal rows, and three normal columns; use the class "wikitable" and at least one example of <code>colspan=</code> or <code>rowspan=</code><br />
* (optional) a WC sound or video file if applicable to your topic<br />
<br />
4. Save your work. Also, ''note the exact source'' of the quote you pulled for this exercise. You're going to need that information for the [[Help:MediaWiki basics/Advanced training|advanced training]] exercise.<br />
<br />
5. Go to [[User talk:Shawndouglas]], select "edit", and under your original header you started from the beginner exercise leave a comment stating you've completed the intermediate exercise. Be sure to sign your comment!</strike><br />
<br />
<strike>1. Open your sandbox for editing. Read over your previously written material concerning your favorite subject in grade school or university. Again, we're going to supplement this material with what we've learned in this training session.<br />
<br />
2. After re-reading your content, think of how you can 1. use "Template:Ombox" effectively in your topic content and 2. apply citations to the text you've written. If your text is lacking in facts, add some information that would require a citation or two.<br />
<br />
3. Integrate the following items into your existing content, modifying the text and its organization as needed:<br />
<br />
one {{ombox}} template, including the following parameters: type, image, style, and text<br />
a section called "External links" (using a header) at the bottom, and under that a bulleted list of at least two external web links relating to your content (refer to the beginner training if you don't remember how to do this)<br />
a "References" section at the bottom of the page (after "External links")<br />
at least three unique citations using proper citation templates<br />
<br />
4. Remember that quote you added to your text in the intermediate training? You were asked to note the exact source of the quote. Well, now is the time to apply the correct citation template to that quote and populate it with the details of the source. Place the citation at the end of the quote, complete with a unique "ref name".<br />
<br />
5. Add your sandbox page to the category "User sandbox". Save your work<br />
<br />
6. Go to User talk:Shawndouglas, select "edit", and under your original header you started from the beginner exercise leave a comment stating you've completed the advanced exercise. Be sure to sign your comment!</strike></div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33977User:Rthiggins/Sandbox2018-09-06T12:46:37Z<p>Rthiggins: Added notice banner to top of page</p>
<hr />
<div>{{ombox<br />
| type = notice<br />
| image =<br />
| style = width960px;<br />
| text = All the writing on this page is original copy I wrote, except quotations and the definitions of pharmacology and medicinal chemistry, which are paraphrased from their respective Wikipedia articles.<br />
}}<br />
<br />
<br />
This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref name="VallanceTheFuture06">{{cite journal |authors=Vallance P.; Smart T.G. |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 |issue=S1|pages=S304–7 |year=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.<br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. <br />
[[File:Aldose reductase 1us0.png | thumb | border | sub | Aldose reductase: Not the sweetest enzyme]]<br />
<br />
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#000000;"| Table 27.1 Strict vs. Loose Serum Glucose Control<ref name="ReichardTheEffect93">{{cite journal |authors=Reichard P.; Nilsson B.Y.; Rosenqvist U.|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |year=1993 |}}</ref><br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.<ref name="WilliamsFoyesPrinciples02">{{cite book |url= |chapter=Chapter 27: Insulin and Oral Hypoglycemic Drugs |title=Foye's Principles of Medicinal Chemistry |author=Williams D.A.; Lemke T.L. |pages=632 |publisher=Lippincott Williams & Wilkins |year=2002 |edition=5th |volume= |isbn=9780683307375 |accessdate=}}</ref></blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/><br />
<br />
<!---Place all category tags here--><br />
[[Category:User sandbox]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33976User:Rthiggins/Sandbox2018-09-06T12:37:11Z<p>Rthiggins: Added category</p>
<hr />
<div>This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref name="VallanceTheFuture06">{{cite journal |authors=Vallance P.; Smart T.G. |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 |issue=S1|pages=S304–7 |year=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.<br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. <br />
[[File:Aldose reductase 1us0.png | thumb | border | sub | Aldose reductase: Not the sweetest enzyme]]<br />
<br />
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#000000;"| Table 27.1 Strict vs. Loose Serum Glucose Control<ref name="ReichardTheEffect93">{{cite journal |authors=Reichard P.; Nilsson B.Y.; Rosenqvist U.|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |year=1993 |}}</ref><br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.<ref name="WilliamsFoyesPrinciples02">{{cite book |url= |chapter=Chapter 27: Insulin and Oral Hypoglycemic Drugs |title=Foye's Principles of Medicinal Chemistry |author=Williams D.A.; Lemke T.L. |pages=632 |publisher=Lippincott Williams & Wilkins |year=2002 |edition=5th |volume= |isbn=9780683307375 |accessdate=}}</ref></blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/><br />
<br />
<!---Place all category tags here--><br />
[[Category:User sandbox]]</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33975User:Rthiggins/Sandbox2018-09-06T12:27:44Z<p>Rthiggins: Updated Reference 3 citation w/template</p>
<hr />
<div>This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref name="VallanceTheFuture06">{{cite journal |authors=Vallance P.; Smart T.G. |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 |issue=S1|pages=S304–7 |year=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.<br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. <br />
[[File:Aldose reductase 1us0.png | thumb | border | sub | Aldose reductase: Not the sweetest enzyme]]<br />
<br />
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#000000;"| Table 27.1 Strict vs. Loose Serum Glucose Control<ref name="ReichardTheEffect93">{{cite journal |authors=Reichard P.; Nilsson B.Y.; Rosenqvist U.|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |year=1993 |}}</ref><br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.<ref name="WilliamsFoyesPrinciples02">{{cite book |url= |chapter=Chapter 27: Insulin and Oral Hypoglycemic Drugs |title=Foye's Principles of Medicinal Chemistry |author=Williams D.A.; Lemke T.L. |pages=632 |publisher=Lippincott Williams & Wilkins |year=2002 |edition=5th |volume= |isbn=9780683307375 |accessdate=}}</ref></blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/></div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33974User:Rthiggins/Sandbox2018-09-06T11:38:33Z<p>Rthiggins: Implemented Shawn's recommended changes</p>
<hr />
<div>This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref name="VallanceTheFuture06">{{cite journal |authors=Vallance P.; Smart T.G. |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 |issue=S1|pages=S304–7 |year=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.<br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. <br />
[[File:Aldose reductase 1us0.png | thumb | border | sub | Aldose reductase: Not the sweetest enzyme]]<br />
<br />
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#000000;"| Table 27.1 Strict vs. Loose Serum Glucose Control<ref name="ReichardTheEffect93">{{cite journal |authors=Reichard P.; Nilsson B.Y.; Rosenqvist U.|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |year=1993 |}}</ref><br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.<ref name="WilliamsFoyesPrinciples02">{{cite book |title=Foye's Principles of Medicinal Chemistry |author=Williams D.A.; Lemke T.L. |year=2002 |pages=632 |edition=5th |publisher=Lippincott Williams & Wilkins |isbn=9780683307375}}</ref></blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/></div>Rthigginshttps://www.limswiki.org/index.php?title=User_talk:Shawndouglas&diff=33966User talk:Shawndouglas2018-09-04T12:42:57Z<p>Rthiggins: Added comment re: intermediate exercise completion</p>
<hr />
<div>This is my talk page. Feel free to comment here if you have questions, suggestions, or need help.<br />
<br />
Simply start a topic by clicking "edit" on this talk page and copy/pasting this material in:<br />
<br />
<pre><br />
==Title of discussion==<br />
<br />
Your discussion<br />
</pre><br />
<br />
Replace "Title of discussion" with your discussion title and "Your discussion" with what you want to say.<br />
<br />
Also, don't forget to sign your post with four tildas like this:<br />
<br />
<pre>~~~~</pre><br />
<br />
Finally, if you are replying to an existing comment, please use the colon (:) in front of your comment, multiple for each further level. Example:<br />
<br />
<br />
<pre><br />
<br />
==Great job on the Laboratory article==<br />
Just wanted to give you kudos for the well-researched article! Keep at it. Joeuser 19:22, 10 February 2011 (EST)<br />
<br />
: Thanks so much! I hope to add more content to the article as time allows. Let me know if I'm missing anything. Janeuser 12:12, 11 February 2011 (EST)<br />
<br />
:: No, I don't see any glaring omissions. I'll watch the article though in case someone else gets crazy with the edits. ~~~~<br />
</pre><br />
==eLabFTW==<br />
<br />
Hello, I added references as requested. The Paris Open Source Summit link doesn't show much for some reason right now, I guess they have a problem; but on this page there is a scheduled talk about this fork by INRIA.<br />
<br />
[[User:NicolasCARPi|NicolasCARPi]] ([[User talk:NicolasCARPi|talk]]) 16:38, 13 October 2016 (UTC)<br />
<br />
==Sponsor Logo Link Broken==<br />
Hi, <br />
The Autoscribe Informatics sponsor logo on the LHS on the top level pages has a broken link.<br />
It should connect to the Autoscribe Ltd. Page<br />
<br />
Also since we have change become much more international we are now known as Autoscribe Informatics not Autoscribe Ltd. Would you be able to help me move the page to "Autoscribe Informatics" and redirect "Autoscribe Ltd." and "Autoscribe Ltd" to "Autoscribe Informatics"<br />
<br />
Thanks,<br />
<br />
Tim<br />
[[User:Tim.daniels|Tim.daniels]] ([[User talk:Tim.daniels|talk]]) 15:02, 10 October 2016 (UTC)<br />
==Updating Sponsor Logo==<br />
<br />
Hi Shawn,<br />
Would you be able to update the Autoscribe Informatics logo on the LHS column please? I've updated the one on the Autoscribe Informatics page but cannot get to the sponsors logos to update that. Thanks Tim.<br />
<br />
[[User:Tim.daniels|Tim.daniels]] ([[User talk:Tim.daniels|talk]]) 13:13, 22 October 2015 (UTC)<br />
<br />
==Thank you!==<br />
<br />
Thanks Shawn and everybody for all the work and contributions so far. <br />
I'm getting value out of the wiki already and am looking forward to more complete content. <br />
There is some great information here so far and the wiki is looking very promising. <br />
I wasn't aware of many of the wiki standards when I started posting, so have posted a lot of non-standard content, but I'm going back and cleaning them up and now I know better when adding new content.<br />
<br />
[[User:Andersjim|Jim Anderson]] 11:08, 12 May 2011 (EDT)<br />
<br />
==Wiki practice==<br />
The wiki practice session is finished. Thanks. [[User:Jdelartigue|Jdelartigue]] 19:08, 22 February 2012 (EST)<br />
<br />
==Embedding HTML==<br />
<br />
There are some neat Youtube videos that I'd like to embed on the chemical industry page. What do you think about turning on the raw html feature? Too risky from a security perspective?<br />
<br />
[[User:Jleecbd|Jleecbd]] 11:00, 9 April 2012 (EDT)<br />
<br />
: I sent a message to John about embedding video in the wiki, specifically in regards to an [http://www.mediawiki.org/wiki/Extension:EmbedVideo EmbedVideo extension]. However, he indicated that the security concerns were enough for him to rather go with links to videos. (This was in context to the [[:Category:Open-source software|open-source software]] articles I was working on.) I assume a similar suggestion to John about opening up [http://www.mediawiki.org/wiki/Manual:$wgRawHtml HTML] would result in the same response. There seems to be a more [http://www.mediawiki.org/wiki/Extension:Secure_HTML secure option] involving hashes and secret keys. That's a little out of my league, but it could be an option if you feel embedding video via HTML would truly enhance the article. Feel free to point John to this extension if you think it's worth a look.<br />
:<br />
: [[User:Shawndouglas|Shawn Douglas]] 14:13, 9 April 2012 (EDT)<br />
<br />
==Completed My First Entry!==<br />
I just wanted to tell you, that it seems that my wiki entry is completed on my sandbox. <br />
<br />
Let me know if it's wrong, I think it is done to the specifications listed [[User:RebeccaFein|RebeccaFein]] 16:17, 3 February 2013 (EST)<br />
<br />
==Updating Pages related to my company Lab-Ally==<br />
<br />
<br />
I am finally getting around to some substantial editing and creation of pages on LIMSWiki that will add new information or correct outdated or inaccurate information related to Lab-Ally, Rescentris, CERF ELN and RSpace ELN. I’m performing these edits under the username “invasifspecies”. I don’t have the slightest interest in contributing anything other than well sourced, accurate information using language that is as neutral and “spin free” as possible. You are welcome to look at any of my edits and call me out on anything that you think is not stylistically compatible with your guidelines. <br />
<br />
The Lab-Ally company page is:<br />
<br />
http://www.limswiki.org/index.php/Lab-Ally_LLC<br />
<br />
I made some edits there December 19th 2016, let me know if you think any of them are inappropriate. I will soon be making pages for CERF ELN RSpace ELN and eCAT. Naturally I will make them as objective as I can. <br />
<br />
I note that the page:<br />
<br />
http://www.limswiki.org/index.php/Inactive_vendor<br />
<br />
has been protected. Unfortunately I see a number of errors there. There is a typo that is preventing the Lab-Ally link from working. There is an extra period in the company name link. See below:<br />
<br />
Rescentris, Inc. CERF United States Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Rescentris entry for more history.<br />
<br />
Since Rescentris is also now defunct and presumably their entry will no longer be updated, I would request changing:<br />
<br />
"Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Rescentris entry for more history.” <br />
<br />
to <br />
<br />
"Was absorbed into irisnote, Inc. then Lab-Ally LLC. See Lab-Ally LLC entry for more history.” <br />
<br />
<br />
Also, the now defunct “irisnote” is missing from this list, but it should be added. See:<br />
<br />
http://www.limswiki.org/index.php/Irisnote,_Inc.<br />
<br />
More information about Lab-Ally and CERF ELN are available at lab-ally.com and cerf-notebook.com<br />
<br />
Regards,<br />
<br />
rjday@lab-ally.com<br />
<br />
[[User:Invasifspecies|Invasifspecies]] ([[User talk:Invasifspecies|talk]]) 00:48, 20 December 2016 (UTC)<br />
<br />
<pre><br />
==email==<br />
<br />
hello Shawn, I sent you an email. Just letting you know, in case you don't check the mail that frequently.<br />
kind regards, Elisabeth<br />
</pre><br />
<pre>~~~~</pre><br />
<br />
==Beginner exercise completed==<br />
I think this is up to snuff, or close. Your tutorial was Grade A outrageously helpful. [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 16:46, 2 September 2018 (UTC)<br />
<br />
Intermediate exercise completed, available [[User:Rthiggins/Sandbox | here]]. -- [[User:Rthiggins|Randall Higgins]] ([[User talk:Rthiggins|talk]]) 12:42, 4 September 2018 (UTC)</div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33965User:Rthiggins/Sandbox2018-09-04T12:35:55Z<p>Rthiggins: Changed table coloring so citation would be visible as hypertext</p>
<hr />
<div>This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref>{{cite journal |authors=Vallance P, Smart TG |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 Suppl 1 |issue= S1|pages=S304–7 |date=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.<br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. <br />
[[File:Aldose reductase 1us0.png | thumb | border | sub | Aldose reductase: Not the sweetest enzyme]]<br />
<br />
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#000000;"| Table 27.1 Strict vs. Loose Serum Glucose Control<ref>{{cite journal |authors=Reichard P, Nilsson BY, Rosenqvist U|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |date=1993 |}}</ref><br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.<ref>{{cite book |title=Foye's Principles of Medicinal Chemistry |author=Williams DA, Lemke TL |year=2002 |pages=632 |edition=5th |publisher=Lippincott Williams & Wilkins |isbn:9780683307375}}</ref></blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/></div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33964User:Rthiggins/Sandbox2018-09-04T12:28:37Z<p>Rthiggins: /* Table 27.1{{cite journal |authors=Reichard P, Nilsson BY, Rosenqvist U|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issu...</p>
<hr />
<div>This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref>{{cite journal |authors=Vallance P, Smart TG |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 Suppl 1 |issue= S1|pages=S304–7 |date=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.<br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. <br />
[[File:Aldose reductase 1us0.png | thumb | border | sub | Aldose reductase: Not the sweetest enzyme]]<br />
<br />
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
<br />
'''<u>Table 27.1</u>'''<ref>{{cite journal |authors=Reichard P, Nilsson BY, Rosenqvist U|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |date=1993 |}}</ref>====<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#118124;"| Table 27.1 Strict vs. Loose Serum Glucose Control<br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.<ref>{{cite book |title=Foye's Principles of Medicinal Chemistry |author=Williams DA, Lemke TL |year=2002 |pages=632 |edition=5th |publisher=Lippincott Williams & Wilkins |isbn:9780683307375}}</ref></blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/></div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33963User:Rthiggins/Sandbox2018-09-04T12:27:32Z<p>Rthiggins: Aldose Reductase Image Placement</p>
<hr />
<div>This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref>{{cite journal |authors=Vallance P, Smart TG |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 Suppl 1 |issue= S1|pages=S304–7 |date=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader.<br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. <br />
[[File:Aldose reductase 1us0.png | thumb | border | sub | Aldose reductase: Not the sweetest enzyme]]<br />
<br />
Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
<br />
====Table 27.1<ref>{{cite journal |authors=Reichard P, Nilsson BY, Rosenqvist U|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |date=1993 |}}</ref>====<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#118124;"| Table 27.1 Strict vs. Loose Serum Glucose Control<br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.<ref>{{cite book |title=Foye's Principles of Medicinal Chemistry |author=Williams DA, Lemke TL |year=2002 |pages=632 |edition=5th |publisher=Lippincott Williams & Wilkins |isbn:9780683307375}}</ref></blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/></div>Rthigginshttps://www.limswiki.org/index.php?title=User:Rthiggins/Sandbox&diff=33962User:Rthiggins/Sandbox2018-09-04T12:06:01Z<p>Rthiggins: Added Table 27.1 citation</p>
<hr />
<div>This is a Sandbox. Sure is a lot of sand in this sandbox.<br />
<br />
==My favorite subject==<br />
I took a '''''lot''''' of classes in pharmacy school. They ran the gamut from [[Biology I]] to [[Pathophysiology]] to Pharmacotherapy, a juggernaut ''12 credit course''. If I had to choose my favorite though, it would be a close race between [https://en.wikipedia.org/wiki/Molecular_biology '''Molecular Biology'''] and [https://en.wikipedia.org/wiki/Pharmacology '''Pharmacology/Medicinal Chemistry'''].<br />
<br />
===Molecular biology===<br />
Molecular biology is a course that examines the molecular basis of biologic functionality. Whereas a course in [[Biology I | general biology]] or anatomy might discuss how food is broken down and processed by the digestive system, molecular biology would look at how the nutrient molecules digestion ultimately produces are transported through the lining of the intestine via specific transporter proteins. It would also discuss how that transport might be altered by the presence of hormones released in response to the body's nutrient needs. For example, if the parathyroid glands in your neck detect a lower than ideal level of calcium in your blood, they release parathyroid hormone, which causes additional transporters for calcium to be turned on in your intestine so you absorb more calcium from the food you eat. I liked this course because it was the first class that really started to answer the 'why?' of biology in detail.<br />
<br />
===Pharmacology/medicinal chemistry===<br />
;Pharmacology<br />
: 1. Pharmacology is the branch of biology concerned with the study of drug action,<ref>{{cite journal |authors=Vallance P, Smart TG |title=The future of pharmacology |journal=British Journal of Pharmacology |volume=147 Suppl 1 |issue= S1|pages=S304–7 |date=January 2006 |pmid=16402118 |pmc=1760753 |doi=10.1038/sj.bjp.0706454 |url=}}</ref> where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism.<br />
<br />
;Medicinal chemistry<br />
: 1. Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties. <br />
: 2. It specifically draws on these disciplines where they are involved with design, chemical synthesis, and development for market of pharmaceutical agents, or bio-active molecules (drugs).<br />
<br />
I really enjoyed this course because:<br />
# It took what I learned in molecular biology and built on it in a way that was directly relevant to pharmacy<br />
# Was taught by Dr. Voigt, who talks and acts like a slightly more mellow Ron Swanson, and who looks like a fireman from the 1970's<br />
<br />
===Combining subjects===<br />
These subjects were studied concurrently at my school, because the material in each supports the other. Here's a great example of that, which also serves as an example of my ability (or lack thereof) to distill complex subject matter into something more digestible to a reader. <br />
<br />
In molecular biology we studied the etiology of diabetes mellitus and its associated complications. Patients with diabetes often experience very high levels of glucose in their blood, which in turn causes high levels of glucose in specific cell types (nerve, epithelial, kidney). High levels of glucose in these cells activates an enzyme called <u>aldose reductase</u>, which converts excess glucose into the sugar alcohol '''sorbitol'''. Because sorbitol cannot exit the cell via the cell membrane, it causes the osmolarity (the amount of stuff dissolved in a solution) of the cell to increase. Cells rely on the osmolarity both inside and outside the cell being maintained in a narrow window for nearly all of the thousands of processes that occur within them. While it can cope with some abnormalities, eventually the high osmolarity overwhelms the cell's ability to do its most basic functions, and the cell dies. <br />
<br />
The risk of developing complications like retinopathy, nephropathy, and neuropathy increases the more times the cell experiences these glucose "spikes." Because a patient's blood glucose level can't be monitored and recorded every second, and patients are often <strike>lazy</strike> less-than-diligent about using their testing meters, we rely on a lab measurement of hemoglobin A<sub>1</sub>C, or HbA<sub>1</sub>C. As the table below illustrates, incidence of complications is lower in patients with lower HbA<sub>1</sub>C levels, which correspond to stricter control over blood glucose levels (fewer spikes).<br />
<br />
====Table 27.1<ref>{{cite journal |authors=Reichard P, Nilsson BY, Rosenqvist U|title=The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. |journal=New England Journal of Medicine |issue=329 |pages=304-309 |date=1993 |}}</ref>====<br />
<br />
{| class="wikitable collapsible" <!--I realize the instructions stated 'wikitable', just practicing--><br />
|-<br />
! colspan="4" style="color:white; background-color:#118124;"| Table 27.1 Strict vs. Loose Serum Glucose Control<br />
|-<br />
! '''Diabetes<br />Complication'''<br />
! '''Strict<br />Control'''<br />
! '''Loose<br />Control'''<br />
! '''No<br />Treatment'''<br />
|-<br />
| HbA<sub>1</sub>C<br />(glycosylated<br />hemoglobin)<br />
| style="background-color:white;" align="center" | 7.1% <br />
| style="background-color:white;" align="center" | 8.5% <br />
| style="background-color:white;" align="center" | 9.5%<br />
|-<br />
| Loss of visual acuity<br />
| style="background-color:white;" align="center" | 14% <br />
| style="background-color:white;" align="center" | 35% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Retinopathy<br />
| style="background-color:white;" align="center" | 27% <br />
| style="background-color:white;" align="center" | 52% <br />
| style="background-color:white;" align="center" | Not measured<br />
|-<br />
| Nephropathy<br />
| style="background-color:white;" align="center" | 0% <br />
| style="background-color:white;" align="center" | 6% <br />
| style="background-color:white;" align="center" | Not measured<br />
|}<br />
<br />
Clearly, higher HbA<sub>1</sub>C levels, which correlate to higher aldose reductase activity, also correlate to more severe diabetic complications. According to Foye's Principles of Medicinal Chemistry:<br />
<blockquote>Complications of diabetes might be prevented if one had drugs which inhibited aldose reductase. A large-scale effort to identify such drugs was mounted in the 1980s, but the only clinical candidate drug, sorbinil, had unacceptable toxicity.</blockquote><br />
Sadly, development of additional drugs in this class, namely zenarestat and zopolrestat, has not produced a safe and effective means to target this enzyme. Instead, focus has shifted to different pharmacologic targets, with agents targeting glucagon-like peptide-1 (GLP-1) being the most promising to date.<br />
<br />
==References==<br />
<references/></div>Rthiggins